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As consumers of goods and services, we expect the law to protect us from potential harm from 
using poor goods or services by having strong requirements of high quality and to provide us 
with adequate means for redress if we are harmed in some way. The object of this chapter in the 
“Legally eHealth” study is to investigate how far, at a European level, the existing legislation on 
consumer protection is adequate to protect users of eHealth systems, tools and services. In this 
context we look at the changing nature of professional relationships in healthcare and the wide 
range of actors implicated in any eHealth relationship. 
 
In the traditional healthcare context, liability for medical care and treatment was restricted to the 
relationship between the patient and the health practitioner (usually a doctor). When a patient 
was harmed as a result of medical negligence or error, the solution was quite simple: the patient 
introduced a civil or criminal lawsuit against the doctor.  
 
However, as the professionalisation of healthcare grew, a new actor appeared in case of medical 
negligence or error: the insurance company of the health practitioner or indeed healthcare 
professionals when the patient is treated by a team of health practitioners or by a hospital service.  
 
As the relationships became more complicated lawyers were frequently asked: Who is liable - the 
health practitioner, the team of health practitioners, the hospital? And what about the liability of 
the author of a second opinion? And does the patient have a part in this? If so, what is it?  
 
And what about the liability of the State, i.e. in the organisation and the monitoring of the health 
activities?  Should we also consider the liability of pharmaceutical or medical device companies, 
or that of the power companies or the telephone provider in case of failure? 
 
If medical liability continues to be considered first in the relationship between the patient and the 
health practitioner (i.e., the patient sues the health practitioner and the health practitioner then, if 
appropriate, sues the person responsible for the damage), the multiplication of intermediaries in 
the field of health services and the number of these with whom the patient has direct contact is 
changing the way in which the liability of the various actors is engaged. The problem arises from 
the fact that the manners in which these liabilities vary, thus potentially creating imbalances, gaps, 
or incoherences in the application of rules to eHealth goods and services.  
 
With the advent of the ‘empowered patient’, more and more citizens are becoming increasingly in 
charge of their own health, without the intervention of a health practitioner. In such cases, with 
the health practitioner entirely out of the picture, the patient stands ‘alone’ against the service 
provider (whether that is a special services operator, a medical device manufacturer or a 
pharmaceutical company), which might be subject to entirely different liability rules altogether. 
Furthermore, if the patient benefits from particular provisions under medical liability laws taking 
into consideration the vulnerabilities specific to the context of health, liability rules applying to 
these other service providers who are not usually associated with health might not provide the 
same types of safeguards for patients. 
 
It is clear that the provision of eHealth products, systems, and services must comply with certain 
levels of quality. Different legal texts have been agreed to provide consumers with a legal 
guarantee of a high level of quality of products and services, and legal redress for any damages 
resulting from sub-standard products or services. The legal texts do not apply exclusively to 
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eHealth, but are instead applied with a general context of service provision and product delivery, 
whether by traditional or via electronic means. 
 
This paper will explore the range of EU level consumer protection legislation which could apply 
to eHealth systems and services, exploring issues such as dissemination of information via 
websites, electronic advertising, contracting online, and delivering of products or services. 
 
The document is divided into four parts: 
 
Part I: A summary description of the key principles of EU level product and services liability 
legislation. Here you will find an outline of the key principles of the legislation with some 
healthcare based examples. 
Part II: A detailed step-by-step analysis of the directives covering: sale of goods, medical 
devices, eCommerce and electronic signatures. The analysis includes a description of all the 
relevant articles of legislation as well as links and references to the source documents. 
Part III: A series of case vignettes, which show the way in which the legislation works. The 
fictional cases will show examples of eHealth applications and explore the data protection 
duties that they imply for the healthcare providers and other actors. 
Part IV: A Source Reference list, where you will find links and reference to all the legal source 
documents discussed in Parts I, II and III.  
EHEALTH GOODS & SERVICES:  
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The concept of the eHealth product is a difficult one because in practice most eHealth products 
will be either software packages and interfaces (Electronic Health Record, Decision Support 
Tool) or they might be hardware devices with embedded software (Radio Frequency 
Identification Location Trackers for locating people and objects; Remotely Controlled Medical 
Devices).  In this chapter we take a broad definition of an eHealth product or services to include 
anything sold to a medical practitioner or directly to a consumer that uses an Internet enabled 
component to deliver benefit. As such it might be an electronic record to be used by the doctor; 
or a monitoring device that includes a web based interface; or even just a simple health 
information portal. Pure medical devices, such as a blood pressure monitor are excluded from 
our definition unless an ‘e’ interface is used. 
 
It is important to note that at present no specific legislation exists at EU level that targets such 
eHealth services and products specifically. Legally, these products will be covered by a range of 
legislation.  
 
Does the sale of goods legislation apply to eHealth goods and 
services? 
 
At a most simple level the sale of any product – be it eHealth or any other, sold to a consumer or 
professional – will be covered by standard contracts for sale of goods. Thus, if the eHealth 
product fails to arrive or arrives late, the standard clauses in the contract will apply which will 
allow the purchaser to pay less or to return the goods. Similarly national legislation based on the 
EC product liability directives (Directive 2001/95/EC and Council Directive 85/375/EEC as 
amended by Directive 1999/34/EC) will ensure that the purchaser has redress if the goods are 
not fit for the purpose sold, while other EC legislation such as Directive 2002/95/EC on the 
Use of Hazardous Substances will provide the purchaser with certainty about certain aspects 
of a product’s quality.   
 
In general therefore in the eHealth arena, one will need to make reference to the relevant national 
legislation based on Directive 1999/44/EC on the Sale of Consumer Goods and associated 
guarantee.  
 
According to this directive, when consumer goods are sold under a contract, the seller must 
deliver goods in conformity of the contract of sale. Moreover, when a commercial guarantee 
exists, the seller or producer who has offered the goods for sale will have to respect some rules 
and will be legally bound to that guarantee as well as to the associated advertising. Any such 
commercial guarantee will have to be made available in writing (or another durable medium, such 
as an e-mail) and will have to contain some information. Anyone selling an eHealth product 
would have to comply with these rules, and conversely a purchaser of an eHealth product would 
have redress under them. 
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Is there general product safety legislation that applies to eHealth 
goods and services? 
 
Directive 2001/95/EC on General Product Safety imposes a general safety requirement for 
any product put on the market for consumers or likely to be used by them. Indeed, the 
producers must put on the market only safe products which are not likely to cause any threat (or 
only a reduced threat in accordance with the nature of use of the product) and which is 
acceptable in view of maintaining a high level of protection for the health and safety of persons. 
In addition, they must provide consumers with relevant information enabling them to assess the 
risks inherent to the product, particularly when it is not obvious, and take appropriate actions to 
avoid these risks (withdrawal from the market, warning to the market consumers, recall products 
already supplied…). The distributors must also comply with other duties, such as keeping the 
relevant documents to help trace the products.  
 
Although most of this legislation is well known to anyone operating in the business world, it is 
fair to say that eHealth products are still rather new and therefore little legal guidance exists on, 
for example, the type of information that is necessary and relevant to allow a purchaser to assess 
the risks of using a product.  
 
However, national authorities have been established to monitor product safety and to take 
appropriate measures to protect consumers. An information system has been put in place that 
imposes collaboration between distributors, producers and the national authorities but also 
between Member States and the European Commission. One such system is RAPEX1, a 
European rapid alert system for dangerous non-food products. It ensures information about 
dangerous products identified in the Member States is quickly circulated between the Member 
States and the Commission. When a product (e.g. a toy, a childcare article or a household 
appliance) is found to be dangerous, the competent national authority takes appropriate action to 
eliminate the risk. It can withdraw the product from the market, recall it from consumers or issue 
warnings. The designated national contact points then informs the European Commission 
(Directorate-General for Health and Consumer Protection) about the product, the risks it poses 
for consumers and the measures taken by the authority to prevent risks and accidents. The 
European Commission publishes weekly overviews of dangerous products and the measures 
taken to eliminate the risks on the Internet.  
 
Could eHealth applications and tools be considered medical 
devices? 
 
Any eHealth device placed on the market and designated as a medical device by the manufacturer 
will be subject to the specific additional rules regarding the medical devices. The medical devices 
sector is covered by three Directives, covering a wide scope of products. The first Directive 
(90/385/EEC), dealing with active implantable medical devices, was adopted in 1990. The 
second Directive (93/42/EEC), adopted in 1993, deals with medical devices in general, while the 
third Directive (98/79/EC), adopted in 1998, deals with in vitro diagnostic medical devices. 
 
The General Directive (93/42/EC) concerning medical devices aims notably to safeguard the 
health and safety of the patients and users by harmonising the conditions for placing medical 
devices on the market and putting them into service. The medical devices must be designed and 
manufactured in such a way that their use does not compromise the safety and health of patients, 
                                                 
1 http://ec.europa.eu/consumers/dyna/rapex/rapex_archives_en.cfm  
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users and other persons when properly installed, maintained and used in accordance with their 
intended purpose.  
 
If a Member State notes that a medical device conforming to the Directive compromises the 
health and/or safety of patients, users or, where applicable, other persons, it shall take all 
appropriate interim measures to withdraw such devices from the market or prohibit or restrict 
their being placed on the market or put into service.   
 
When the products manufactured are electrical or electronic equipment, like IT or 
telecommunications equipment, they must respect Directive 2002/95/EC, known as the 
“Restrictions on the use of Hazardous Substances in electronic equipment” (or RoHS), bans the 
sale of new electrical and electronic equipment containing more than agreed levels of lead, 
cadmium, mercury, hexavalent chromium, polybrominated biphenyl (PBB) and polybrominated 
diphenyl ether (PBDE) flame retardants. This law requires manufacturers to find new materials 
and develop new engineering processes for the creation of common electronic equipment.    
 
The Directive does not currently apply to medical devices even if the definition of a medical 
device could cover electronic equipment and software. The question of applicability of the RoHS 
Directive on eHealth hardware manufacturers is controversial: a possible interpretation would be 
that hardware sold to medical equipment manufacturers to run medical equipment but which 
retain all of the normal functions of a computer will have to respect the RoHS Directive. 
However, computer or other components installed into medical equipment as components that 
do not act as a separate computer but only operate the medical device are considered as medical 
device and are not concerned by RoHS Directive.  
 
The Directive relating to active implantable medical devices states that active medical devices and 
active implantable medical devices may be placed on the market and put into service only if they 
do not compromise the safety and health of patients and users. Member States must take 
appropriate measures to withdraw dangerous devices from the market. 
 
The Directive on In Vitro Diagnostic Medical Devices imposes that in vitro medical devices and 
their accessories, the latter considered as in vitro diagnostic medical devices as such, may be 
placed on the market and put into service only if they comply with some requirements. This 
induces the obligation of Member States to monitor the security and the quality of these devices.  
Member States must take appropriate measures to withdraw dangerous devices from the market.  
 
Directive 2001/83 on the Community code relating to medicinal products for human use 
imposes that no medicinal product may be placed on the market unless a marketing authorisation 
has been issued by the national competent authority.  
 
Finally, it should be noted that national, European and international standards bodies are 
developing standards that apply to eHealth products. A particular example is the CEN standard 
for EHRs (CEN ENV 13606) or the American HL7 standard for EHR or indeed the industry 
DICOM standard for medical digital images2. While these standards are not legally binding, they 
do provide a baseline against which disputes about the quality of an eHealth product covered by 
a standard might be assessed.  
 
                                                 
2 see http://www.openehr.org/standards/t_cen.htm  
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How will consumers and professional users be protected if an 
eHealth product or services causes damage? 
 
Council Directive 85/374/EEC on Defective Products will apply to eHealth products in the 
same way as it applies to any product sold on the European market. This Directive aims at 
ensuring a high level of consumer protection against damage caused to health or property by a 
defective product. It aims also to reduce the disparities between national liability laws, which 
distort competition and restrict the free movement of goods. It implements a system that extends 
the producer’s liability (‘strict liability’) in order to protect consumers.  
 
Council Directive 85/374/EEC establishes the principle of objective liability or liability without 
fault of the producer, importer and under some conditions the supplier, for damage caused by a 
defective product. As a result, the producer, importer or supplier will be liable and must pay 
compensation for damages caused to persons or properties resulting from a defect. The injured 
person does not have to prove that the producer was at fault or negligent; he simply needs to 
prove that damage arose, that a defect in the product exists and that there is a causal relationship 
between defect and damage (concept of ‘strict liability’).  
 
For example, if defective software used to drive an infusion pump causes an incorrect dosage to 
be administered and the patient is caused harm, then the patient will not need to prove the fault 
of the manufacturer of the software, but will just have to prove that he was injured, not the fact 
that the software does not provide the safety which a patient is entitled to expect as well as the 
link between the dosage error and the injury. 
 
However, in order to strike a reasonable balance between the interest of the consumer and the 
need to encourage innovation and technological development, there are some rules protecting the 
producer. Indeed, under some particular circumstances, the producer may be exonerated from all 
liability. Moreover, the liability is not unlimited but rather a limited period of liability has been set 
to three years from the moment the consumer becomes aware of the damage, the defect and the 
identity of the producer, and the liability is limited ten years after the producer has put the 
product into circulation.  
 
What about liability for an eHealth service? 
 
An eHealth service might be passive, such as delivering general medical information through a 
website, or might be active in giving medical advice or specific decision support to clinicians, or 
might involve the collection of biomedical data for remote monitoring by a clinician. Such a 
service might conceivably cause damage to someone relying on the service. A citizen might 
follow bad advice and fall ill, or even die; a clinician might follow the recommended procedure 
after using a decision support tool and might harm a patient; or a remote monitoring service 
might fail to transmit relevant data thereby putting a patient’s life at risk. 
 
In many such cases a causal link will exist between the harm suffered and a defective good. Thus 
if an error exists in a decision-support software, the doctor who relied on the software would 
have a claim based in Council Directive 85/374/EEC as described above. 
 
There is currently, however, no general European harmonisation of liability rules for services in 
which no defect can be found in a device. Therefore, liability for services is governed by ordinary 
rules of law applicable in the Member States. An exception to this may exist if a service is 
supplied by wholly electronic means, in which case the eCommerce Directive (Directive 
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2000/31/EC) might apply.  These issues are further considered below looking at questions on 
health related websites and health related eCommerce. 
 
Who is legally responsible for Health related websites? 
 
From the moment a service is proposed via Internet at the individual request of a recipient of 
services and that this service is normally provided for remuneration, it is considered as an 
information society service, and accordingly the information duties established by the 
eCommerce Directive have to be respected.  
 
Thus, a doctor or other party running a health related website, will have to inform the users of his 
identity, address, VAT number, etc. These information duties aim to enable the recipient of the 
service (professionals or not) to identify properly the service provider and to ensure transparency 
of his/her activities. 
 
In essence the purpose of these information duties is to allow the ultimate users to know against 
whom they can seek redress if they should need to do so. 
 
This principle of Transparency of provider of site is also included within the Commission 
Communication (COM(2002)667) on Quality Criteria for Health related Websites. This 
Communication aims to increase the reliability of health related websites and also include other 
quality criteria that health related web sites must comply with, such as transparency of the 
purpose of the website, respect of privacy, accessibility adapted to the target audience, etc. Those 
quality criteria may serve as reference in the development of quality initiatives for health related 
websites. 
 
If a health related website includes commercial communications (any type of communications 
promoting the goods, services or the image of a company), the eCommerce Directive imposes 
additional duties. It requires, among other things, that commercial communication should be 
clearly identifiable as such and the person on whose behalf the commercial communication is 
made must be clearly identifiable as well. The purpose is to avoid any confusion between 
advertising and any other type of information. The eCommerce Directive does not replace other 
legal texts that impose particular rules or restrictions relative to advertisement concerning 
regulated professions such as doctors or dentists. 
 
In the context of health related websites it should be noted that Directive 2001/83/EC explicitly 
prohibits direct-to-consumer-advertising (DTCA) of prescription medication. This applies 
whether the advertisement is made on paper or electronically. However, given that direct to 
consumer advertising of prescription medication is permitted in the USA, many European 
citizens find American advertising on the Internet and buy directly from the USA. 
 
Moreover, a health related website might advertise services or products not covered by the ban 
on advertising of prescription only pharmaceuticals. In these cases, Directive 2005/29/EC 
concerning unfair business-to-consumer commercial practices may apply. According to this 
directive, any commercial practice (including advertising) directly connected with the promotion, 
sale or supply of a product (including service) to consumers must be fair. This Directive explains 
when a practice should be considered as unfair. All practices breaching the professional diligence 
requirements that materially distort the behaviour of the average consumer will be considered as 
unfair, and therefore banned. 
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For instance, it is forbidden to promote a medicinal product as 100% guarantee without any side 
effects when the trader must reasonably know that the tests made cannot completely exclude the 
possibility of all potential side effects.  
 
Directive 2005/29/EC thus bans unfair commercial practices such as misleading practices, failing 
to provide the consumer with the information needed or with false information, and aggressive 
practices, like harassment, coercion or undue influence. The directive provides a black list of 
prohibited practices. It lists the practices that will be considered as unfair in all circumstances, 
such as unsolicited supply or use of bait advertising (for instance when the lower-price product is 
not available). 
 
Directive 2005/29/EC integrates the previously existing EU level rules applicable to business-to-
consumer transactions. These rules were established by the directives on misleading and 
comparative advertising (84/450/EEC as modified by 97/55/EC), which are still applicable to 
business-to-business relationships. These directives prohibit misleading advertisings and fix the 
conditions allowing comparative advertising. 
 
When the advertisements made on websites concern medicinal products, some particular rules 
apply. Directive 2001/83 on the Community code relating to medicinal products for human use 
authorises the advertising of medicinal products only if some conditions are respected (obtaining 
of marketing authorisation, no marketing for medicines only available on medical prescription or 
requiring intervention of a medical practitioner,…). Moreover, the advertising must encourage 
the rational use of the medicinal product through an objective and reasonable presentation of its 
properties.  
 
Are there any special rules for contracts for eHealth goods or 
services? 
 
Much eHealth business will necessarily involve the conclusion of contracts. On the whole, 
normal national contract law will apply, transposing where applicable EU level directives. The 
conclusion of eHealth contracts could occur for the delivery of eHealth products and for the 
provision of eHealth services. The latter includes the online provision of medical care, such as 
tele-monitoring.  
 
Generally, such a contract will be governed by normal national contract law, being simply a 
contract for a service. Where such a contract is made between parties in different European 
countries the usual rules about cross border contracting will apply.  This means that the contracts 
will be drawn up under the law of the state in which either the purchaser or provider resides. A 
number of legislative instruments at the EU level have already been adopted to ensure that 
parties to such contracts can know in advance under which jurisdiction any eventual dispute will 
be solved. The “Brussels Regulation” (Council Regulation 44/2001 of 22 December 2000) 
concerning jurisdiction and the recognition and enforcement of judgments in civil and 
commercial matters, and the 1980 Rome Convention on the law applicable to contractual 
obligations are the reference points at EU level.  
 
A further area of legislation could apply to a contract concluded by electronic means. When the 
possibility of online contracting is offered, Directive 1997/7/EC on distance contracts applies, as 
well as some rules of the eCommerce Directive (2000/31/EC). It should be noted that the 
Directive on distance contracts applies when the contract is concluded between a professional 
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and a consumer, while the eCommerce Directive applies to business-to-consumer transactions 
and to business-to-business transactions.  
 
If either directive applies to an eHealth transaction, they may impose on eHealth professionals a 
duty to provide consumers/patients/users with some information. The Distance Contracts 
Directive (1997/7/EC) imposes on the supplier a duty to provide the recipient with written 
information (or another durable medium such as an e-mail or an online information), prior to the 
conclusion of the contract, relative to his identity, the product or service and the price. The 
eCommerce Directive provides for a list of information relative to the formation of the contracts, 
such as the different technical steps to follow in order to conclude the contract or relative to the 
technical means proposed to identify errors.  
 
Can electronic signatures be used to conclude eHealth contracts? 
 
eHealth professionals may use electronic signatures in order to authenticate their identity, their 
profession, as well as the fact that they are registered with a professional body. A particular 
example of the use of eSignatures in health will arise in the case of electronic prescriptions, where 
it will be necessary to ensure that the signatory has the title of doctor and probably also that he is 
registered with the social security body, which allows the reimbursement of the medical fees.  
 
An electronic signature aims to allow the person receiving electronic data (like an e-mail, an 
ePrescription, etc.) to be able to identify the origin/author of the information/data 
(identification) as well as to verify that the information has not been altered during its 
communication (integrity).  
 
Different kinds of electronic signatures exist, from the very simple ones (the insertion of a 
scanned hand-written signature within an electronic document), to the most sophisticated ones, 
such as the signatures based on public key cryptography. This last kind of signatures implies the 
intervention of a trusted third party (Certification Service Providers) who creates certificates in 
order to allow the recipient to check the identity of the sender and the integrity of the message. 
 
Directive 1999/93/EC on electronic signatures provides the conditions for the legal recognition 
of any electronic signature. When the signature is based on a public key cryptography system 
(advanced electronic signature), for example, it has to be accepted and recognised, including in a 
court of law. But every kind of electronic signature may benefit from some legal effects. 
 
The main principle of the Directive is the introduction of a legal equivalence between the hand-
written signature and the advanced electronic signature based on a qualified certificate meeting 
certain requirements. When the conditions are met, the advanced electronic signatures are 
considered as having the same effect as a hand-written signature. 
 
Moreover, the legal equivalence cannot be a priori denied for any electronic signature as such. The 
fact that a signature is in electronic form and does not meet the requirements that make it 
possible to affirm automatically its equivalence with the hand-written signature does not allow the 
judges to refuse it. The legal effectiveness and admissibility in legal proceedings of an electronic 
signature cannot be refused simply because it is in electronic form or because it does not enjoy 
the conditions of an advanced electronic signature. Therefore, the legal value of a non-advanced 
eSignature must be determined case by case and may not be rejected a priori.  
 
For instance, if a doctor uses his scanned signature for an ePrescription and after, in the 
framework of a trial, it must be proved that the prescription was coming from him/her, the judge 
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cannot a priori refuse to consider this type of signature but will have to analyse, possibly with the 
help of experts, the evidence value of this signature. The advantage of the use of advanced 
electronic signature is that, in the context of a trial, this type of signature is directly considered as 





From the discussion above we can see that although a wide range of legislation will apply to the 
provision of eHealth services and goods, there is no EU level legislation targeted especially at 
such transactions. In general, consumers will be protected if they suffer harm from an eHealth 
good just as they are protected if they suffer harm from any other good. This means that any 
consumer can expect reasonable levels of safety, and can sue for damages using the strict liability 
rules.   
 
We have noted also that the provision of eHealth services as such are regulated primarily through 
national contract law, which will apply to domestic as well as cross-border contracts. Special rules 
may apply when the eHealth good or service consists of or uses a medical device or if it is made 
using certain hazardous substances. 
 
We have noted also that if an eHealth good or service advertised on a website and a contract for 
such a good or service is concluded online, then special rules about eCommerce and distance 
contracting will apply to eHealth goods and services as they apply to any other good or service – 
this includes also the prohibition of the sale of prescription medication except by authorised 
providers and the direct to consumer advertising of such pharmaceuticals. 
 
It should be noted, however, that there is no special legislation at EU level covering eHealth 
goods and services and that moreover there is only limited legislation that regulates the quality of 
services as opposed to goods (with the exception of financial services). 
 
Having set out the general landscape with respect to liability for eHealth goods and services the 
following section gives a detailed analysis of the various EU Directives described above. 
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PART II: DETAILED ANALYSIS OF THE LEGAL TEXTS 
 
I. DIRECTIVE 1999/44 ON THE SALE OF CONSUMER GOODS 
AND ASSOCIATED GUARANTEES  
 
A. Key concepts 
 
1. CONSUMER 
The consumer is the same as in Directive 1997/7: it is any natural person who, in the contracts 
covered by this Directive, is acting for purposes which are not related to his trade, business or 
profession. 
 
2. CONSUMER GOODS 
Consumer goods are any tangible movable item (except goods sold by authority of law, water and 
gas where they are not put up for sale in a limited volume or set quantity, and electricity).  
 
3. SELLER 
The seller is any natural or legal person who, under a contract, sells consumer goods in the course 
of his trade, business or profession.  
 
4. PRODUCER 
The producer is the manufacturer of consumer goods, the importer of consumer goods into the 
territory of the Community or any person purporting to be a producer by placing his name, 
trademark or other distinctive sign on the consumer goods. 
 
5. GUARANTEE 
A guarantee is any undertaking by a seller or producer to the consumer, given without extra 
charge, to reimburse the price paid or to replace, repair or handle consumer goods in any way if 
they do not meet the specifications set out in the guarantee statement or in the relevant 
advertising.  
 
This term covers only commercial guarantees, which may be voluntarily proposed by the sellers 
and not the ‘legal guarantee’, which exists without the need of the will of the seller, just by effect 
of the law. The commercial guarantee offers protection in addition to that due by law. The legal 
guarantee is described in this Directive as the ‘principle of conformity with the contract’.  
 
6. REPAIR 
Repair means bringing consumer goods into conformity with the contract of sale. 
 
B. Principle of conformity with the contract 
 
The seller has to deliver to the consumer goods that are in conformity with the contract of sale. 
 
Consumer goods are presumed to be in conformity with the contract if they:  
(a) comply with the description given by the seller and possess the qualities of the goods 
which the seller has held out to the consumer as a sample or model;  
(b) are fit for the purposes for which goods of the same type are normally used; 
(c) are fit for any particular purpose for which the consumer requires them and which he 
Comment [C1]:  = in french 
« volontee » ? 
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made known to the seller at the time of conclusion of the contract and which the seller has 
accepted;  
(d) show the quality and performance which are normal in goods of the same type and which 
the consumer can reasonably expect, given the nature of the goods and taking into account 
any public statements on the specific characteristics of the goods made about them by the 
seller, the producer or his representative, particularly in advertising or on labelling.  
 




The seller shall be liable to the consumer for any lack of conformity that exists at the time the 
goods were delivered. 
 
Any lack of conformity that becomes apparent within six months of delivery of the goods shall 
be presumed to have existed at the time of delivery unless proved otherwise or if this 
presumption is incompatible with the nature of the goods or the nature of the lack of conformity. 
 
Where the final seller is liable to the consumer because of a lack of conformity resulting from an 
act or omission by the producer, a previous seller in the same chain of contracts or any other 
intermediary, the final seller shall be entitled to seek action against the person responsible.  
 
2. EXEMPTION OF LIABILITY 
The seller is not liable if, at the time the contract was concluded, the consumer was aware, or 
could not reasonably be unaware of, the lack of conformity, or if the lack of conformity has its 
origin in materials supplied by the consumer. 
 
The seller shall not be bound by public statements, as referred to in point B (d), if he: 
• shows that he was not, and could not reasonably have been, aware of the statement in 
question,  
• shows that, by the time of conclusion of the contract, the statement had been corrected, 
or 
• shows that the decision to buy the consumer goods could not have been influenced by 
the statement. 
 
3. CONSUMER’S RIGHT  
In the case of a lack of conformity, the consumer shall be entitled: 
• to have the goods brought into conformity free of charge by repair or replacement, 
within a reasonable time and without any significant inconvenience to him or her, or  
• to have an appropriate reduction made to the price or the contract rescinded if repair or 
replacement is impossible or disproportionate, or if the seller has not remedied the 
shortcoming within a reasonable period of major inconvenience to the consumer. 
 
The consumer is not entitled to have the contract rescinded if the lack of conformity is minor. 
 
4. LIMIT OF PERIOD OF LIABILITY 
In order to benefit from the protection, the consumer must inform the seller of the lack of 
conformity within a period of 2 months from the date on which he detected such lack of 
conformity.  
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Moreover, the seller’s liability is limited to a two-year period from the date of the delivery of 
goods.  
 
D. Rules relating to the commercial guarantees 
 
Any commercial guarantee offered by a seller or producer will be legally binding under the 
conditions laid down in the guarantee document and the associated advertising.  
 
The guarantee shall:  
• state that the consumer has legal rights under applicable national legislation governing the 
sale of consumer goods and make clear that those rights are not affected by the 
guarantee,  
• state its contents in plain intelligible language and indicate the conditions for making claims 
under the guarantee, notably the duration and territorial scope of the guarantee as well as 
the name and address of the guarantor.  
 
On request by the consumer, the guarantee shall be made available in writing or feature in 
another durable medium available and accessible to him or her.  
 
 
II. DIRECTIVE 2001/95 ON GENERAL PRODUCT SAFETY 
 
A. Key concepts 
 
1. PRODUCT 
The term ‘product’ means any product - including in the context of providing a service - which is 
intended for consumers or likely, under reasonably foreseeable conditions, to be used by 
consumers even if not intended for them, and is supplied or made available, whether for 
consideration or not, in the course of a commercial activity, and whether new, used or 
reconditioned. 
 
Therefore, products initially reserved for professional use that are subsequently made available to 
consumer are also considered as product.   
 
This definition shall not apply to second-hand products supplied as antiques or as products to be 
repaired or reconditioned prior to being used, provided that the supplier clearly informs the 
person to whom he supplies the product to that effect. 
 
2. SAFE PRODUCT 
A safe product is any product which, under normal and reasonably foreseeable conditions of use 
including duration, and where applicable, putting into service, installation and maintenance 
requirements, does not present any risk or only the minimum risks compatible with the product’s 
use, considered to be acceptable and consistent with a high level of protection for the safety and 
health of persons. 
 
Some elements should be taken into consideration: 
• the characteristics of the product, such as its composition, packaging, instructions for 
assembly and, where applicable, for installation and maintenance; 
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• the effect on other products, where it is reasonably foreseeable that it will be used with 
other products; 
• the presentation of the product, the labelling, any warnings and instructions for its use 
and disposal and any other indication or information regarding the product;  
• the categories of consumers at risk when using the product, in particular children and the 
elderly. 
 
3. DANGEROUS PRODUCT 
A product is dangerous when it does not meet the definition of ‘safe product’. 
 
4. SERIOUS RISK 
Serious risk means any serious risk, including those the effects of which are not immediate, 
requiring rapid intervention by the public authorities. 
 
5. PRODUCER 
The producer is:  
• the manufacturer of the product, when he is established in the Community, and any other 
person presenting him or her self as the manufacturer by affixing to the product his 
name, trade mark or other distinctive mark, or the person who reconditions the product;  
• the manufacturer's representative, when the manufacturer is not established in the 
Community or, if there is no representative established in the Community, the importer 
of the product;  
• other professionals in the supply chain, insofar as their activities may affect the safety 
properties of a product. 
 
6. DISTRIBUTOR 
The distributor is any professional in the supply chain whose activity does not affect the safety 
properties of a product. 
 
7. RECALL 
Recall is any measure aimed at achieving the return of a dangerous product that has already been 
supplied or made available to consumers by the producer or distributor. 
 
8. WITHDRAWAL 
Withdrawal is any measure aimed at preventing the distribution, display and offer of a product 
dangerous to the consumer. 
 
B. Scope of the General Product Safety Directive 
 
The Directive applies to any product insofar as no specific provisions among the European 
Community laws governing the safety of the product are concerned or if sectoral legislation is 
sufficient.  
 
The provision of services is excluded from the scope of the Directive but the products supplied 
to consumer in the context of a service are covered.  
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C. General safety requirement 
 
1. PRINCIPLE  
Producers are obliged to place only safe products on the market for consumers or likely to be 
used by them.  
 
2. HOW TO ASSESS THE COMPLIANCE WITH THE SAFETY REQUIREMENT? 
Some criteria are proposed in order to assess if a product complies with the safety requirement: 
 
• A product is deemed safe once it conforms to the specific Community provisions 
governing its safety; 
• In the absence of such provisions, the product must comply with the specific national 
regulations of the Member State in which it is being marketed or sold; 
• In the absence of such provisions, it must conform to the voluntary national standards 
which transpose the European standards;  
• In the absence of these, the product’s compliance is determined according to different 
elements (such as the reasonable consumer expectations concerning safety, the state of 
the art and technology, codes of good practice, Commission recommendations, …). 
 
D. Other obligations of producers and obligations of distributors 
 
The producers must provide consumers with the relevant information to enable them to assess 
the risks inherent in a product, particularly when these are not obvious. They must also indicate, 
by means of product or its packaging, the identity and details of the producer and the product 
reference.   
 
The producers must also take measures to avoid such risks, such as withdrawing the products 
from the market, informing consumers, recalling products that have already been supplied to 
consumers, etc.  
 
The distributors are obliged to supply products that comply with the general safety requirements, 
to monitor the safety of products placed on the market, to keep and provide the documentation 
ensuring that the products can be traced, and to collaborate with competent authorities to avoid 
the risks.  
 
E. The duty of the Member States to put in place National 
Authorities 
 
National authorities are established or designated by the Member States in order to monitor the 
product safety and to take appropriate measures as regards risky products.  
 
This national authority must ensure that producers and distributors comply with their duties and 
are entitled to ensure the product safety by organising checks on safety properties, by imposing 
producers to warn adequately on the possible risks, by prohibiting dangerous products to be 
marketed, by alerting consumers on the risks of a product already marketed and by organising 
recalls and destruction of products when necessary.  
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F. Information system 
 
Directive 2001/95 aims to create an efficient information system in order to help Member States, 
national authorities and consumers to react quickly in order to avoid or reduce any harm to the 
health and safety of persons. 
 
The producers and distributors who discover that a product is dangerous must notify the 
competent national authority and collaborate with it.  
 
The European Commission is in charge of reinforcing cooperation between the national 
authorities and of promoting exchange of information and expertise by setting up a European 
product safety network between the national authorities.  
 
When a national authority adopts a measure for the reason of a serious risk that may have an 
effect beyond its territory, it shall inform the European Commission via Rapex (a system for the 
rapid exchange of information between the Member States and the European Commission) of 
the identity of the product, the risks, the measures taken and the information on the distribution, 
including the destination countries. This information will be communicated to the other Member 
States.  
 
The European Commission can also approve rapid measures at Community level when it 
becomes aware of a serious risk in various Member States. After consulting the Member States 
and a scientific committee when scientific questions arise, the Commission may adopt a decision 
(like the recall of the product, for instance) to be implemented by the Member States within less 
than 20 days.  
 
 
III. COUNCIL DIRECTIVE 85/374/EEC CONCERNING 
LIABILITY FOR DEFECTIVE PRODUCTS 
 
A. Key concepts 
 
1. PRODUCT 
A product is all movables, which have been industrially produced, even though incorporated into 
another movable or into an immovable. It includes, since the modification of the Directive in 
1999, primary agricultural products, but it does not include immovables.  
 
2. PRODUCER 
The ‘producer’ means: 
• the manufacturer of a finished product,  
• the producer of any raw material or the manufacturer of a component part, 
• any person who, by putting his name, trade mark or other distinguishing feature on the 
product presents him or her self as its producer. Therefore, there is no loophole of 
protection if the name that appears on the product is not the one of the real 
manufacturer or if the product is anonymous. 
 
Moreover, the importer who imports into the Community a product for sale, hire, leasing or any 
form of distribution in the course of his business shall be deemed to be a producer within the 
meaning of this Directive.  
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3. DEFECTIVE PRODUCT 
A product is defective when it does not provide the safety which a person is entitled to expect, 
taking all circumstances into account, including: 
• the presentation of the product; 
• the use to which it could reasonably be expected that the product would be put; 
• the time when the product was put into circulation. 
 
Therefore, the safe nature of the product must be judged at the time the product was put into 
circulation. A product will not be considered as defective for the sole reason that a better product 
is consequently put into circulation. The safety is assessed by excluding any misuse of the product 
not reasonable under the circumstances. 
 
B. The principle of liability without fault 
 
1. WHO IS LIABLE? 
The producer is liable for damage caused by a product defect even without fault. The producer is 
submitted to these rules of liability without fault from the moment when he put the product into 
circulation. According to the European Convention on products liability in regard to personal 
injury and death of 27 January 1977, a product has been ‘put into circulation’ when the producer 
has delivered it to another person. 
 
The person who imports into the Community a product for sale, hire, leasing or any form of 
distribution in the course of his business shall be deemed to be a producer and will therefore be 
responsible as a producer. The underlying idea is to protect the consumer even if the producer is 
a foreigner and is not established in the Community.  
 
If the producer (or the importer) cannot be identified, each supplier of the product shall be 
treated as its producer unless he informs the injured person, within a reasonable time, of the 
identity of the producer or of the person who supplied him or her with the product.  
 
There are therefore different levels of persons’ liability: primary (for the producer or the importer 
that will be treated like the producer) or subsidiary (supplier).  
 
If more than one person is liable for the same damage, there will be joint liability. 
 
2. WHAT HAS TO BE PROVED?  
The injured person has to prove: 
• the actual damage; and 
• the defect of the product; and 
• the causal relationship between the damage and the defect. 
 
It is not necessary to prove the negligence or the fault of the producer or the importer. The 
producer (or the importer, the supplier) will be liable even he did not made any fault. The 
European Convention on products liability in regard to personal injury and death of 27 January 
1977 introduced this principle since it was considered that the notion of “fault” no longer 
constituted a satisfactory basis for the system of products’ liability in an era of mass-production, 
where technical developments, advertising and sales methods had created special risks, which the 
consumer could not be expected to accept.  
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3. EXEMPTION OR REDUCTION OF LIABILITY 
The Directive establishes a list of hypotheses under which, the producer may be exempted from 
liability. The producer will have to defend him or her self successfully by proving that: 
• he did not put the product into circulation (for instance, it was put into circulation by a 
person who stole it); or 
• that the defect causing the damage did not exist when the product was put into 
circulation or that the effect came into being afterwards (the producer therefore prove 
that the defect was not attributable to him or her); or 
• that the product was not manufactured or distributed for profit-making sale or in the 
course of his business; or 
• that the defect is due to compliance of the product with mandatory regulations issued by 
the public authorities; or 
• that the state of scientific and technical knowledge at the time when the product was put 
into circulation was not such as to enable the defect to be discovered; or 
• in the case of a manufacturer of a component of the final product, that the defect is 
attributable to the design of the product in which component has been fitted or to the 
instructions given by the product manufacturer. 
 
The producer’s liability is not reduced when the damage is caused both by a defect in the product 
and by the act or omission of a third party. In this case, the producer may try to recover his loss 
against the third party.  
 
However, when the damage is caused both by the defect of the product and the fault of the 
injured person or any person for whom the injured person is responsible (like the legal 
representative, the employee or the children), the producer’s liability may be reduced or 
disallowed. 
 
The producer is not allowed to limit or exclude his liability by contractual provisions.  
 
C. The damage covered 
 
The producer shall be liable to pay compensation for:  
• the damage caused by death or personal injuries; 
• the damage to an item of property ordinarily intended for private use or consumption or 
used by the injured person mainly for his own private use or consumption, with a 
threshold of EUR 500. 
 
The damage caused to the defective product itself is not covered. The Directive does not prevent 
Member States from establishing compensation to non-material damages.  
 
D. Limit of period of liability 
 
The injured person has a limitation period of three years to seek compensation. This period starts 
from the day on which the plaintiff became aware, or should reasonably have become aware of 
the damage, the defect and the identity of the producer. After that, no further compensation will 
be possible.  
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Moreover, in any case the producer’s liability is limited to a period of ten years from the date on 
which the producer put the product into circulation. This time limit is intended to preserve a 
balance between consumers’ and producers’ interests.  
 
 
IV. DIRECTIVE 90/385/EEC RELATING TO ACTIVE 
IMPLANTABLE MEDICAL DEVICES 
 
A. Key concepts 
 
1. MEDICAL DEVICE 
Medical device means any instrument, apparatus, appliance, material or other article, whether 
used alone or in combination, together with any accessories or software for its proper 
functioning, intended by the manufacturer to be used for human beings in the:  
 
• diagnosis, prevention, monitoring, treatment or alleviation of disease or injury,  
• investigation, replacement or modification of the anatomy or of a physiological process,  
• control of conception,  
 
and which does not achieve its principal intended action by pharmacological, chemical, 
immunological or metabolic means, but which may be assisted in its function by such means;  
 
2. ACTIVE MEDICAL DEVICE 
Active medical device means any medical device relying for its functioning on a source of 
electrical energy or any source of power other than that directly generated by the human body or 
gravity.  
 
3. ACTIVE IMPLANTABLE MEDICAL DEVICE 
Active implantable medical device means any active medical device which is intended to be totally 
or partially introduced, surgically or medically, into the human body or by medical intervention 
into a natural orifice, and which is intended to remain after the procedure. 
 
4. CUSTOM-MADE DEVICE 
Custom-made device' means any active implantable medical device specifically made in 
accordance with a medical specialist's written prescription which gives, under his responsibility, 
specific design characteristics and is intended to be used only for an individual named patient. 
 
5. DEVICE INTENDED FOR CLINICAL INVESTIGATION 
Device intended for clinical investigation' means any active implantable medical device intended 
for use by a specialist doctor when conducting investigations in an adequate human clinical 
environment. 
 
6. INTENDED PURPOSE 
Intended purpose means the use for which the medical device is intended and for which it is 
suited according to the data supplied by the manufacturer in the instructions.  
 
7. PUTTING INTO SERVICE 
Putting into service means making available to the medical profession for implantation. 
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B. Authorisation and Evaluation of Active Implantable Medical 
Devices 
 
Where an active implantable medical device is intended to administer a medicinal product, that 
substance shall be subject to the system of marketing authorization for medicinal product.  
 
Where an active implantable medical device incorporates, as an integral part, a substance which, if 





Active Medical Device and Active Implantable Medical Device may be placed on the market and 
put into service only if they do not compromise the safety and health of patients, users and, 
where applicable, other persons when properly implanted, maintained and used in accordance 
with their intended purposes. 
 
D. Essential Requirements for Active Implantable Medical 
Devices 
 
Active Medical Device and Active Implantable Medical Device and Custom-made Device must 
satisfy the essential requirements set out in the Annex 1 of the Directive, which shall apply to 
them account being taken of the intended purpose of the devices concerned.  
 
E. Withdrawal of dangerous devices 
 
Where a Member State finds that an Active Medical Device or an Active Implantable Medical 
Device, correctly put into service and used in accordance with their intended purpose, may 
compromise the health and/or safety of patients, users or, where applicable, other persons, it 
shall take all appropriate measures to withdraw such devices from the market or prohibit or 
restrict their being placed on the market or their being put into service.  
 
In this case the Member State shall immediately inform the Commission of any such measure, 
indicating the reasons for its decision and, in particular, whether non-compliance with this 
Directive is due to:  
(a) failure to meet the essential requirements, where the device does not meet in full or in 
part the standards referred to in Article 5;  
(b) incorrect application of those standards;  
(c) shortcomings in the standards themselves.  
 
F. Information system on dangerous devices 
 
Member States shall take the necessary steps to ensure that information brought to their 
knowledge regarding the incidents mentioned below involving a device is recorded and evaluated 
in a centralized manner:  
(a) any deterioration in the characteristics and performances of a device, as well as any 
inaccuracies in the instruction leaflet which might lead to or might have led to the death 
of a patient or to a deterioration in his state of health;  
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(b) any technical or medical reason resulting in withdrawal of a device from the market by 
the manufacturer.  
 
G. CE Mark 
 
In principle Active Implantable Medical Device must bear the CE Mark of Conformity.  
 
The EC mark of conformity must appear in a visible, legible and indelible form on the sterile 
pack and, where appropriate, on the sales packaging, if any, and on the instruction leaflet.  
 
It must be accompanied by the logo of the notified body.  
 
 
V. DIRECTIVE 2001/83 ON THE MEDICINAL PRODUCTS FOR 
HUMAN USE 
 
A. Key concepts 
 
1. MEDICINAL PRODUCT 
A medicinal product is any substance or combination of substances presented for treating or 
preventing disease in human beings or which may be administered to human beings with a view 
to making a medical diagnosis or to restoring, correcting or modifying physiological functions.  
 
2. MEDICINAL PRESCRIPTION 
A medicinal prescription is any medicinal prescription issued by a qualified professional person. 
 
3. ADVERTISING OF MEDICINAL PRODUCTS 
Advertising of medicinal products is any form of door-to-door information, canvassing activity 
or inducement designed to promote the prescription, supply, sale or consumption of medicinal 
products. It includes in particular:  
• advertising of medicinal products to the general public, 
• advertising of medicinal products to persons qualified to prescribe or supply them, 
• visits by medical sales representatives to persons qualified to prescribe medicinal 
products, 
• the supply of samples, 
• the provision of inducements to prescribe or supply medicinal products by the gift, offer 
or promise of any benefit or bonus, whether in money or in kind, except when their 
intrinsic value is minimal, 
• sponsorship of promotional meetings attended by persons qualified to prescribe or 
supply medicinal products, 
• sponsorship of scientific congresses attended by persons qualified to prescribe or supply 
medicinal products and in particular payment of their travelling and accommodation 




Directive 2001/83 applies to industrially produced medicinal products for human use intended to 
be placed on the market in Member States. 
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C. Principle of authorisation  
 
No medicinal product may be placed on the market, distributed, manufactured of imported 
unless a marketing authorisation has been issued by the competent authorities of the relevant 
Member State. A marketing authorisation may only be granted to an applicant established in the 
Community. 
 
Before issuing an authorisation, the competent authority will check if the outer packaging, the 
immediate packaging and the package leaflet contain the necessary information (such as the name 
of the product, route of administration, adverse reactions, expiry date etc.).  
 
An authorisation holder may submit a request for recognition of this authorisation to other 
Member States.  
 
D. Advertising  
 
No advertising may be made for a medicinal product for which a marketing authorisation has not 
been granted (except in the case of homeopathic medicines).  
 
The advertising must encourage the rational use of the medicinal product, by presenting it 
objectively and without exaggerating its properties and the advertising shall not be misleading. 
 
All parts of the advertising of a medicinal product must comply with the particular specifications 
listed in the summary of product characteristics (article 11 of the Directive), for instance, the 
name of the medicinal product, information for the correct use, pharmaceutical form, contra-
indications, adverse reactions, special precautions for use, posology and method of 
administration, special warnings, etc. Some specific information must appear when the 
advertising is made to the general public and other type of information when the advertising is 
made to the persons qualified to prescribe or supply such products (doctors, pharmacists, …). 
 
Some additional requirements are established when the advertising is made to the general public 
(and not only to the persons qualified to prescribe or supply medicinal products). In this case, it 
may not concern medicinal products that are available only on medical prescription, that contain 
psychotropic or narcotic substances or that may not be advertised to the general public because, 
by virtue of their composition and purpose, they are intended and designed for use only with the 
intervention of a medical practitioner for diagnostic purposes or for the prescription or 
monitoring of treatment, with the advice of the pharmacist, if necessary.  
 
Some therapeutic indications may not be mentioned in advertising to the general public, such as 
tuberculosis, sexually transmitted diseases, other serious infectious diseases, cancer and other 
tumoral diseases, chronic insomnia, diabetes and other metabolic illnesses. 
 
Direct distribution of medicinal products to the public for promotional purposes is prohibited as 
well as advertising the cost of which may be reimbursed.  
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The advertising of medicinal products to the general public may not include any information 
which:  
• gives the impression that a medical consultation or surgical operation is unnecessary, in 
particular by offering a diagnosis or by suggesting treatment by mail; 
• compares the medicinal products with other treatments or products; 
• suggests that the health of the subject can be enhanced by taking the medicine or affected 
by not taking it; 
• is directed exclusively or principally at children; 
• refers to a recommendation by scientists, health professionals or persons who are neither 
of the foregoing but who, because of their celebrity, could encourage the consumption of 
medicinal products; 
• suggests that the medicinal product is a foodstuff, cosmetic or other consumer product; 
• suggests that the safety or efficacy of the medicinal product is due to the fact that it is 
natural; 
• could, by a description or detailed representation of a case history, lead to erroneous self-
diagnosis; 
• refers, in improper, alarming or misleading terms, to claims of recovery; 
• uses, in improper, alarming or misleading terms, pictorial representations of changes in 
the human body caused by disease or injury, or of the action of a medicinal product on 
the human body; 
• mentions that the medicinal product has been granted a marketing authorisation. 
 
 
VI. COUNCIL DIRECTIVE 1993/42 CONCERNING MEDICAL 
DEVICES 
 
A. Key concepts 
 
1. MEDICAL DEVICE 
According to the Directive, 'medical device' “means any instrument, apparatus, appliance, 
material or other article, whether used alone or in combination, including the software necessary 
for its proper application intended by the manufacturer to be used for human beings for the 
purpose of:  
• diagnosis, prevention, monitoring, treatment or alleviation of disease,  
• diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap,  
• investigation, replacement or modification of the anatomy or of a physiological process,  
• control of conception, 
  
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its function by 
such means”. 
 
The accessories which is not a medical devices as such but is intended specifically to be used 
together with a device to enable it to be used in accordance with the use of the device intended 
by the manufacturer of the device is shall be treated as medical devices in their own right. 
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Electronic equipment and software are included within the definition of medical device when 
they are manufactured or promoted for medical purpose. According to the Guidelines relating to 
the Medical Devices Directives, software related to the functioning of a medical device is an 
accessory or a device on its own right if it is placed on the market separately from the related 
device. When the software helps for the diagnostic (like image enhancing software for diagnostic 
purposes), or is a therapeutic tool, then it is considered as a medical device. This is not the case 
for software used for the administration of general patient data.  
 
When a product has multiple purposes (such a PC, printer, screen, etc.), it could be considered as 
a medical device only if a specific medical purpose is assigned to them.  
 
2. MANUFACTURER 
'Manufacturer' means the natural or legal person with responsibility for the design, manufacture, 
packaging and labelling of a device before it is placed on the market under his own name, 
regardless of whether these operations are carried out by that person himself or on his behalf by 
a third party.  
 
The obligations of this Directive to be met by manufacturers also apply to the natural or legal 
person who assembles, packages, processes, fully refurbishes and/or labels one or more ready-
made products and/or assigns to them their intended purpose as a device with a view to their 
being placed on the market under his own name. This subparagraph does not apply to the person 
who, while not a manufacturer within the meaning of the first subparagraph, assembles or adapts 
devices already on the market to their intended purpose for an individual patient. 
 
B. General safety requirement 
 
Manufacturer are obliged to place on the market or to put into service only medical devices that 
do not compromise the safety and health of patients users and, where applicable, other persons 
when properly installed, maintained and used in accordance with their intended purpose. 
 
The manufacturer must design and manufacture medical devices in such a way that some 
‘essential requirements’ are met, such as to take into account the generally acknowledged state of 
the art and to eliminate or reduce risks as far as possible (like the risks linked to the toxicity of the 
materials and their incompatibility with biological tissues and cells, or the risks of contamination 
for persons involved in the transport, storage and use of the devices, and for patients). 
 
Devices which are in conformity with national provisions transposing the existing harmonised 
standards will be presumed by Member States to comply with the essential requirements laid 
down by the Directive. 
 
Devices other than those which are custom-made or intended for clinical investigation must bear 
a CE conformity marking when they are placed on the market. 
 
C. Possibility for the MS to withdraw medical devices from the 
market 
 
Where a Member States ascertains that a medical devices may compromise the health and/or 
safety of patients, users or, where applicable, other persons, it must take all appropriate measures 
to withdraw such devices. Such decision must be motivated and notified to the manufacturer. 
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The Member State must also inform the European Commission of any such measures, indicating 
the reasons for its decision. 
 
If the Commission, after a consultation with the parties concerned finds that the measures are 
justified, it shall immediately so inform the Member State which took the initiative and the other 
Member States. When the Commission considers that the measures are unjustified, it shall 
immediately so inform the Member State which took the initiative and the manufacturer or his 
authorized representative established within the Community. 
 
D. Information system in case of incidents 
 
Member States must ensure that incidents arising following placing of devices on the market will 
be recorded and evaluated centrally, for instance by requiring medical practitioners or the medical 
institutions to inform the competent authorities of any incidents. 
 
After carrying out an assessment, if possible together with the manufacturer, Member States shall, 
inform the Commission and the other Member States of the incidents for which relevant 
measures have been taken or are contemplated.  
 
 
VII. DIRECTIVE 98/79 ON IN VITRO DIAGNOSTIC MEDICAL 
DEVICES 
 
The Directive applies to in vitro diagnostic medical devices and their accessories that are treated 
as in vitro diagnostic medical devices in their own right.  
 
A. Key Concepts 
 
1. MEDICAL DEVICE 
Medical device means any instrument, apparatus, appliance, material or other article, whether 
used alone or in combination, including the software necessary for its proper application, 
intended by the manufacturer to be used for human beings for the purpose of: 
• diagnosis, prevention, monitoring, treatment or alleviation of disease, 
• diagnosis, monitoring, treatment, alleviation or compensation for an injury or handicap, 
• investigation, replacement or modification of the anatomy or of a physiological process, 
• control of conception, 
 
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its function by 
such means;  
 
2. IN VITRO DIAGNOSTIC MEDICAL DEVICE 
In vitro diagnostic medical device means any medical device which is a reagent, reagent product, 
calibrator, control material, kit, instrument, apparatus, equipment, or system, whether used alone 
or in combination, intended by the manufacturer to be used in vitro for the examination of 
specimens, including blood and tissue donations, derived from the human body, solely or 
principally for the purpose of providing information: 
 
• concerning a physiological or pathological state, or 
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• concerning a congenital abnormality, or 
• to determine the safety and compatibility with potential recipients, or 
• to monitor therapeutic measures. 
 
Specimen receptacles are considered to be in vitro diagnostic medical devices. 'Specimen 
receptacles` are those devices, whether vacuum-type or not, specifically intended by their 
manufacturers for the primary containment and preservation of specimens derived from the 
human body for the purpose of in vitro diagnostic examination. 
 
Products for general laboratory use are not in vitro diagnostic medical devices unless such 
products, in view of their characteristics, are specifically intended by their manufacturer to be 
used for in vitro diagnostic examination.  
 
3. ACCESSORIES 
Accessory means an article that, while not being an in vitro diagnostic medical device, is intended 
specifically by its manufacturer to be used together with a device to enable that device to be used 
in accordance with its intended purpose. 
 
For the purposes of this definition, invasive sampling devices or devices that are directly applied 
to the human body for the purpose of obtaining a specimen within the meaning of Directive 
93/42/EEC shall not be considered to be accessories to in vitro diagnostic medical devices. 
 
4. DEVICE FOR SELF-TESTING 
Device for self-testing means any device intended by the manufacturer to be able to be used by 
lay persons in a home environment;  
 
5. DEVICE FOR PERFORMANCE EVALUATION 
Device for performance evaluation means any device intended by the manufacturer to be subject 
to one or more performance evaluation studies in laboratories for medical analyses or in other 
appropriate environments outside his own premises.  
 
6. MANUFACTURER 
Manufacturer means the natural or legal person with responsibility for the design, manufacture, 
packaging and labelling of a device before it is placed on the market under his own name, 
regardless of whether these operations are carried out by that person himself or on his behalf by 
a third party. 
 
The obligations to be met by manufacturers also apply to the natural or legal person who 
assembles, packages, processes, fully refurbishes and/or labels one or more ready-made products 
and/or assigns to them their intended purpose as devices with a view to their being placed on the 
market under his own name. This subparagraph does not apply to the person who, while not a 
manufacturer within the meaning of the first subparagraph, assembles or adapts devices already 
on the market to their intended purpose for an individual patient. 
 
7. AUTHORIZED REPRESENTATIVE 
Authorised representative means any natural or legal person established in the Community who, 
explicitly designated by the manufacturer, acts and may be addressed by authorities and bodies in 
the Community instead of the manufacturer with regard to the latter's obligations under this 
Directive. 
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8. INTENDED PURPOSE 
Intended purpose means the use for which the device is intended according to the data supplied 
by the manufacturer on the labelling, in the instructions for use and/or in promotional materials. 
 
9. PLACING ON THE MARKET 
Placing on the market` means the first making available in return for payment or free of charge 
of a device other than a device intended for performance evaluation with a view to distribution 
and/or use on the Community market, regardless of whether it is new or fully refurbished. 
 
10. PUTTING INTO SERVICE 
Putting into service means the stage at which a device has been made available to the final user as 
being ready for use on the Community market for the first time for its intended purpose. 
 
11. CALIBRATION AND CONTROL MATERIALS 
Calibration and control materials refer to any substance, material or article intended by their 
manufacturer either to establish measurement relationships or to verify the performance 




Such devices may be placed on the market and/or put into service only if they comply with the 
requirements laid down in the Directive when duly supplied and properly installed, maintained 
and used in accordance with their intended purpose.  
 
This involves the obligation of Member States to monitor the security and quality of these 
devices.  
 
There must not be any obstacles to the placing on the market or the putting into service of 
devices bearing the EC marking.  
 
C. Essential Requirements 
 
Devices must meet the essential requirements set out in the Annex I of the Directive, taking 
account of the intended purpose of the devices concerned. 
 
D. Dangerous Devices 
 
Where a Member State ascertains that the devices, when correctly installed, maintained and used 
for their intended purpose may compromise the health and/or safety of patients, users or, where 
applicable, other persons, or the safety of property, it shall take all appropriate interim measures 
to withdraw such devices from the market or prohibit or restrict their being placed on the market 
or put into service. The Member State shall immediately inform the Commission of any such 
measures, indicating the reasons for its decision and, in particular, whether non-compliance is due 
to: 
(a) failure to meet the essential requirements;  
(b) incorrect application of the standards referred to in Article 5, insofar as it is claimed 
that the standards have been applied;  
(c) shortcomings in the standards themselves. 
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E. Registration duty 
 
Any manufacturer who places devices on the market under his own name shall notify the 
competent authorities of the Member State in which he has his registered place of business: 
• of the address of the registered place of business, 
• of information relating to the reagents, reagent products and calibration and control 
materials in terms of common technological characteristics and/or analytes and of any 
significant change thereto including discontinuation of placing on the market; for other 
devices, the appropriate indications, 
• in the case of devices covered by Annex II and of devices for self-testing, of all data 
allowing for identification of such devices, the analytical and, where appropriate, 
diagnostic parameters as referred to in Annex I, part A, section 3, the outcome of 
performance evaluation pursuant to Annex VIII, certificates and any significant change 
thereto, including discontinuation of placing on the market. 
 
 
VIII. DIRECTIVE 2000/31 ON ELECTRONIC COMMERCE 
 
A. Key Concepts 
 
1. INFORMATION SOCIETY SERVICES 
An information society service is any service normally provided for remuneration, at a distance, 
by electronic means and at the individual request of a recipient of services (like the Internet). It 
covers services between enterprises or between enterprises and consumers, which are paid 
directly from the recipient (on-line transactions) or which are financed by indirect means, like by 
advertising income or sponsoring.  
 
Activities which by their very nature cannot be carried out at a distance and by electronic means, 
such as medical advice requiring the physical examination of a patient, are not information 
society services. When the physical examination of the patient is not necessary, then the service 
may be considered as information society service, such as: 
• Websites of doctors promoting their activities; 
• On-line selling of medicines (ePharmacy); 
• On-line advice that does not require the physical examination of the patient if a fee is 
paid or if it is financed by advertising or sponsorship; 
• On-line databases of information accessible for medical professionals or consumers if a 
fee is paid or if it is financed by advertising or sponsorship (even indirectly). 
 
2. SERVICE PROVIDER 
A service provider is any natural or legal person providing an information society service.  
 
3. RECIPIENT OF THE SERVICE 
The recipient of the service is any natural or legal person who, for professional ends or otherwise, 
uses an information society service, in particular for the purposes of seeking information or 
making it accessible.  
 
4. COMMERCIAL COMMUNICATION 
Commercial communications are any form of communication designed to promote, directly or 
indirectly, the goods, services or image of a company, organisation or person pursuing a 
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commercial activity. Information allowing direct access to the activity of the company, 
organisation or person, in particular a domain name or an e-mail address is not a commercial 
communication.  
 
B. The principle of country of origin 
 
The country of origin principle provides that the law applicable to an eCommerce activity will be 
the law of the country in which the service provider is established. For example, if an electronic 
health care service provider, established in Italy, provides on-line information to doctors in 
different places in Europe, it will fall under the Italian law.  
 
However, there are exceptions to the country of origin principle and notably Member States have 
the right to derogate from this principle i.e. if it is necessary for the protection of public health.  
 
C. Information duty for information society services 
 
1. GENERAL INFORMATION 
In addition to other information requirements, the Information Society Service provider has to 
render easily, directly and permanently accessible to the recipients of the service and competent 
authorities, at least the following information: 
• the name of the service provider;  
• the geographic address at which the service provider is established;  
• the details of the service provider, including his electronic mail address, which allow him 
to be contacted rapidly and communicated with in a direct and effective manner;  
• where the service provider is registered in a trade or similar public register, the trade 
register in which the service provider is entered and his registration number, or equivalent 
means of identification in that register;  
• where the activity is subject to an authorisation scheme, like the sale of pharmaceutical 
products, the particulars of the relevant supervisory authority. 
 
2. REGULATED PROFESSIONS 
Regulated professions have to provide more additional information when delivery information 
society services: 
• any professional body or similar institution with which the service provider is registered, 
• the professional title and the Member State where it has been granted, 
• a reference to the applicable professional rules in the Member State of establishment and 
the means to access them. 
 
3. VALUE ADDED TAX NUMBER 
The Value Added Tax number has to appear when offering information society services whether 
the service provider undertakes an activity subject to VAT.  
 
4. PRICE INFORMATION 
Finally, where information society services refer to prices, these prices are to be indicated clearly 
and unambiguously and, in particular, must indicate whether they are inclusive of tax and delivery 
costs. 
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D. Commercial communications: possibility and information duty  
 
The provider of an Information Society Service has to comply with some special conditions 
when using commercial communications or unsolicited commercial communications for 
promoting eHealth services or products. There are also special rules applicable to commercial 
communications from regulated professions.  
 
1. GENERAL CONDITIONS TO COMMERCIAL COMMUNICATIONS 
In addition to other information requirements, when the commercial communication is part of, 
or constitutes, an information society service, some additional information have to appear:  
• the commercial communication has to be clearly identifiable as such;  
• the natural or legal person on whose behalf the commercial communication is made has 
to be clearly identifiable;  
• promotional offers, such as discounts, premiums and gifts, where permitted in the 
Member State where the service provider is established, has to be clearly identifiable as 
such, and the conditions which are to be met to qualify for them has to be easily 
accessible and be presented clearly and unambiguously;  
• promotional competitions or games, where permitted in the Member State where the 
service provider is established, has to be clearly identifiable as such, and the conditions 
for participation has to be easily accessible and be presented clearly and unambiguously. 
 
2. SPECIAL CONDITIONS TO UNSOLICITED COMMERCIAL COMMUNICATIONS 
Additionally where unsolicited commercial communication by electronic mail are used by the 
provider of an eHealth Service and are permitted by the Member State where the service provider 
is established, such commercial communication has to be identifiable clearly and unambiguously 
as such as soon as the unsolicited commercial communication is received by the recipient. 
 
The providers of an eHealth Service undertaking unsolicited commercial communications by 
electronic mail has to consult regularly and respect the opt-out registers in which natural persons 
not wishing to receive such commercial communications can register themselves. 
 
3. SPECIAL CONDITIONS TO COMMERCIAL COMMUNICATIONS FROM REGULATED 
PROFESSIONS 
Regulated professions (like lawyers, doctors, and dentists, amongst others) are allowed to make 
use of commercial communications. But to benefit from this authorisation these professionals 
must comply with the professional rules regarding in particular, the independence, dignity and 
honour of the profession, professional secrecy and fairness towards clients and other members of 
the profession. 
 
Regarding this issue, professional associations and bodies are encouraged to establish codes of 
conduct at European level in order to determine the types of information that can be given for 
the purposes of commercial communication in conformity with the rules regarding in particular, 
the independence, dignity and honour of the profession, professional secrecy and fairness 
towards clients and other members of the profession. 
 
If the commercial communication conforms to these rules, the service provider must still comply 
with the general conditions applicable to commercial communications and with the special 
conditions applicable to unsolicited commercial communications i.e. he should clearly identify it 
as such. Moreover, the natural or legal person on whose behalf the commercial communication is 
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made shall also be clearly identifiable. Promotional offers and promotional competitions shall 
also be clearly identifiable.  
 
E. The conclusion of contract by electronic means 
 
The conclusion of contract by electronic means is allowed in eHealth - regarding the provision of 
products and services. However, it does not change special rules applicable in the healthcare 
sector as for example these concerning the prescription of medicines. 
 
But the conclusion of contract by electronic means has to comply with some special conditions. 
These conditions are applicable in eHealth.  
 
1. PRINCIPLE 
All the Member State Legal Systems have to allow the conclusion of contracts by electronic 
means. In particular no legal requirements applicable to the contractual process may create 
obstacles for the use of electronic contracts nor deprived these contracts of legal effectiveness 
and validity on account of their having been made by electronic means.  
 
2. EXCEPTIONS 
Nevertheless Member States may decide that some contracts may not be concluded by electronic 
means such as those falling into one of the following categories: 
• contracts that create or transfer rights in real estate, except for rental rights;  
• contracts requiring by law the involvement of courts, public authorities or professions 
exercising public authority;  
• contracts of suretyship granted and on collateral securities furnished by persons acting for 
purposes outside their trade, business or profession;  
• contracts governed by family law or by the law of succession. 
 
3. THE CONCLUSION OF CONTRACTS BY ELECTRONIC MEANS 
The online conclusion of contract follows a kind of “two step procedure”:  
(a) information to provide the recipient of the service with and  
(b) the placing of the order.  
 
(a) Information from the service provider to the service recipient 
 
(a.1) Information regarding the contractual process 
 
(a.1.1) Business to consumer 
In addition to other information requirements and prior to the placing of the order by the service 
recipient, the service provider has to provide the service recipient with at least the following 
information clearly, comprehensibly and unambiguously: 
• the different technical steps to follow to conclude the contract;  
• whether or not the concluded contract will be filed by the service provider and whether it 
will be accessible;  
• the technical means for identifying and correcting input errors prior to the placing of the 
order;  
• the languages offered for the conclusion of the contract. 
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(a.1.2) Business to business 
Parties who are not consumers may agree otherwise on the information to provide regarding the 
contractual process.  
 
(a.1.3) Exception 
The information duty regarding the contractual process does not apply to contracts concluded 
exclusively by exchange of electronic mail or by equivalent individual communications. 
 
(a.2) Indication and information regarding codes of conduct 
 
(a.2.1) Business to consumer 
The service provider must indicate any relevant codes of conduct to which he subscribes and 
information on how those codes can be consulted electronically. 
 
(a.2.2) Business to business 
Parties who are not consumers may agree otherwise on the indication and information regarding 
codes of conduct.  
 
(a.2.3) Exception 
The indication and information duty regarding codes of conduct does not apply to contracts 
concluded exclusively by exchange of electronic mail or by equivalent individual communications. 
 
(a.3) Availability of Contract Terms and General Conditions 
Contract terms and general conditions provided to the service recipient must be made available in 
a way that allows him or her to store and reproduce them. This duty equally applies to contracts 
concluded exclusively by exchange of electronic mail or by equivalent individual communications.  
 
(b) Placing of the order 
 
(b.1) Acknowledgement receipt of the order and of the moment of the reception of the order  
 
(b.1.1) Business to consumer 
In cases where the service recipient places his order through technological means, the following 
principles apply: 
• the service provider has to acknowledge the receipt of the recipient's order without undue 
delay and by electronic means, 
• the order and the acknowledgement of receipt are deemed to be received when the 
parties to whom they are addressed are able to access them. 
 
(b.1.2) Business to business 
Parties who are not consumers may agree otherwise on the principles applicable to the 
acknowledgement of the order and to the moment of the reception of the order and of the 
acknowledgement receipt.  
 
(b.1.3) Exception 
The service provider has not to acknowledge the receipt of the recipient's order without undue 
delay and by electronic means in case of contracts concluded exclusively by exchange of 
electronic mail or by equivalent individual communications. 
 
 (b.2) Possibility of prior identification and correction of input errors 
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(b.2.1) Business to consumer 
Prior to the placing of the order the service provider has to make available to the recipient of the 
service appropriate, effective and accessible technical means allowing him to identify and correct 
input errors. 
 
(b.2.2) Business to business 
Parties who are not consumers may agree otherwise on the possibility to identify and to correct 
input errors prior the placing of the order.  
 
(b.2.3) Exception 
The possibility to identify and to correct input errors prior the placing of the order does not 
apply to contracts concluded exclusively by exchange of electronic mail or by equivalent 
individual communications. 
 
F. Liability of intermediary service providers 
 
The Directive establishes a special exoneration system of liability for some categories of Internet 
intermediaries (mere conduit, caching and hosting) in detailed circumstances.  
 
1. MERE CONDUIT  
The “Mere Conduit” is an information society service consisting of: 
• the transmission in a communication network of information provided by a recipient of 
the service,  
• or the provision of access to a communication network. 
 
When providing such “Mere Conduit” service, the service provider is not liable for the 
information transmitted. To benefit from this exemption, the provider has to comply with several 
cumulative conditions: 
• the provider does not initiate the transmission;  
• the provider does not select the receiver of the transmission; and 
• the provider does not select or modify the information contained in the transmission. 
 
The acts of transmission and of provision of access include the automatic, intermediate and 
transient storage of the information transmitted in so far as this takes place for the sole purpose 
of carrying out the transmission in the communication network, and provided that the 
information is not stored for any period longer than is reasonably necessary for the transmission. 
 
This liability exemption does not affect the possibility for a court or administrative authority of 
requiring the service provider to terminate or prevent an infringement. 
 
For example, if the electronic communication operator or Internet access provider plays only a 
passive role in transmitting information from a third party, he won’t be liable.  
 
2.  CACHING 
The “Caching” is an information society service consisting of the transmission in a 
communication network of information provided by a recipient of the service.  
 
When providing such “Caching” service, the service provider is not liable for the automatic, 
intermediate and temporary storage of that information, performed for the sole purpose of 
making more efficient the information's onward transmission to other recipients of the service 
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upon their request. To benefit from this exemption, the provider has to comply with several 
cumulative conditions: 
• the provider does not modify the information;  
• the provider complies with conditions on access to the information;  
• the provider complies with rules regarding the updating of the information, specified in a 
manner widely recognised and used by industry;  
• the provider does not interfere with the lawful use of technology, widely recognised and 
used by industry, to obtain data on the use of the information; and 
• the provider acts expeditiously to remove or to disable access to the information it has 
stored upon obtaining actual knowledge of the fact that the information at the initial 
source of the transmission has been removed from the network, or access to it has been 
disabled, or that a court or an administrative authority has ordered such removal or 
disablement. 
 
This liability exemption does not affect the possibility for a court or administrative authority of 
requiring the service provider to terminate or prevent an infringement. 
 
3. HOSTING 
The “Hosting” service consists of the storage of information provided by a recipient of the 
service.  
 
When providing such “Hosting” service, the service provider is not liable for the information 
stored at the request of a recipient of the service. To benefit from this exemption, the provider 
has to comply with several cumulative conditions: 
• the provider does not have actual knowledge of illegal activity or information and, as 
regards claims for damages, is not aware of facts or circumstances from which the illegal 
activity or information is apparent; or 
• the provider, upon obtaining such knowledge or awareness, acts expeditiously to remove 
or to disable access to the information. 
 
The service provider may not benefit from this exemption when the recipient of the service is 
acting under the authority or the control of the provider. 
 
This liability exemption does not affect the possibility for a court or administrative authority of 
requiring the service provider to terminate or prevent an infringement, nor does it affect the 
possibility of establishing procedures governing the removal or disabling of access to 
information. 
 
For example the Internet service provider that gives server space for a company’s or an 
individual’s website will not be liable for the information stored when he does not know about 
the illegality of the information or if he does know it, he prevents any access to it.  
 
When the provider has a control on the information (acting like an editor), he cannot benefit 
from this exoneration system.  
 
4. NO GENERAL OBLIGATION TO MONITOR INFORMATION 
When providing these three information services (“Mere Conduit”, “Caching” or “Hosting”), 
providers can not be obliged to monitor the information which they transmit or store, nor to 
seek actively facts or circumstances indicating illegal activity. 
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But they may be obliged to promptly inform the competent public authorities of alleged illegal 
activities undertaken or information provided by recipients of their service or obligations to 
communicate to the competent authorities, at their request, information enabling the 
identification of recipients of their service with whom they have storage agreements. 
 
 
IX. DIRECTIVE 1999/93 ON A COMMUNITY FRAMEWORK FOR 
ELECTRONIC SIGNATURES  
 
A. Key concepts 
 
1. ELECTRONIC SIGNATURE 
An electronic signature means data in electronic form which are attached to or logically 
associated with other electronic data and which serve as a method of authentication.  
 
2. AN ADVANCED ELECTRONIC SIGNATURE 
An advanced electronic signature is an electronic signature that meets the following requirements: 
(a) it is uniquely linked to the signatory; 
(b) it is capable of identifying the signatory; 
(c) it is created using means that the signatory can maintain under his sole control; and 
(d) it is linked to the data to which it relates in such a manner that any subsequent change 
of the data is detectable. 
 
3. THE SIGNATORY 
The signatory is the person who holds a signature-creation device and acts either on his own 
behalf or on behalf of the natural or legal person or entity he represents. 
 
4. A CERTIFICATE 
A certificate is an electronic attestation that links signature-verification data to a person and 
confirms the identity of that person. 
 
5. A QUALIFIED CERTIFICATE 
A qualified certificate is a certificate that meets the requirements laid down in Annex I of the 
Directive 1999/93 on a Community framework for an electronic signature and is provided by a 
certification-service-provider who fulfils the requirements laid down in Annex II of the same 
Directive.  
 
6. A CERTIFICATION SERVICE PROVIDER 
A certification-service-provider is an entity or a legal or natural person who issues certificates or 
provides other services related to electronic signatures. 
 
B. Legal recognition of electronic signatures 
 
1. ADVANCED ELECTRONIC SIGNATURES 
An advanced electronic signature (which is uniquely linked to the signatory; is capable of 
identifying the signatory; is created using means that the signatory can maintain under his sole 
control; and is linked to the data to which it relates in such a manner that any subsequent change 
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of the data is detectable) will enjoy the same evidence value of an handwritten signature if 
complying with the following requirements:  
• It must be based on a qualified certificate; 
• The certificate must have been issued by a service-provider who possesses the 
requirements foreseen in Annex II to the Directive; 
• It must be created by a secure-signature-creation device which meets the requirements 
laid down in Annex III; 
 
This type of electronic signature constitutes an implicit reference model for the Community 
legislator. By using this type of eSignature, which may be accredited by a national body, the 
signatory does not take the risk that his signature will not be accepted as evidence in a court 
procedure.  
 
2. NON ADVANCED ELECTRONIC SIGNATURES 
A non-advanced electronic signature or which does not comply with the requirements allowing 
the automatic legal equivalence with a hand-written signature does also produce legal effects. 
 
Indeed, the Directive includes a non-discriminatory principle that states that an electronic 
signature could not be legally discriminated solely on the grounds that it is: 
• in electronic form, or 
• not based upon a qualified certificate, or 
• not based upon a qualified certificate issued by an accredited certification-service-
provider, or 
• not created by a secure signature-creation device. 
 
In practice, when a conflict occurs, the admissibility as well as the evidence value cannot be a 
priori rejected by the judge, simply for the reason that it is a signature in a electronic format or 
because it does not respect the conditions of an advanced electronic signature.  
 
The main objective of the European legislator was to be technologically neutral and not to 
exclude electronic signatures that are not considered as the most sophisticated ones.  
 
The appreciation of the legal value will have to be considered case by case by the judges, 
depending on the particular circumstances.  
 
 
X. DIRECTIVE 2005/29 CONCERNING UNFAIR BUSINESS-TO-
CONSUMER COMMERCIAL PRACTICES 
 
A. Key concepts 
 
1. BUSINESS-TO-CONSUMER COMMERCIAL PRACTICES 
Business-to-consumer commercial practices are any act, omission, course of conduct or 
representation, commercial communication including advertising and marketing, by a trader, 
directly connected with the promotion, sale or supply of a product to consumers. 
 
2. PRODUCT 
A product is any good or service including immovable property, rights and obligations. 
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3. PROFESSIONAL DILIGENCE 
Professional diligence is the standard of special skill and care which a trader may reasonably be 
expected to exercise towards consumers, commensurate with honest market practice and/or the 
general principle of good faith in the trader's field of activity. 
 
4. TO DISTORT MATERIALLY THE BEHAVIOUR OF THE AVERAGE CONSUMER 
Using a commercial practice to impair appreciably the consumer's ability to make an informed 
decision, thereby causing the consumer to take a transactional decision that he would not have 
taken otherwise. 
 
5. UNFAIR COMMERCIAL PRACTICES 
A commercial practice is unfair when: 
• it is contrary to the requirements of professional diligence; and 
• it materially distorts or could materially distort the economic behaviour of the average 
consumer. 
 
In particular, commercial practices shall be unfair if they are misleading or aggressive. 
 
6. MISLEADING PRACTICES 
A commercial practice may mislead by action or by omission.  
 
A practice is misleading by action if it gives false information or deceives or is likely to deceive 
the average consumer, even if the information is factually correct. 
 
A practice is misleading by omission if it omits material information that the average consumer 
needs prior to take a decision on the transaction or it provides unclear, ambiguous information 
and therefore distorts the transactional decision that the average consumer would have taken 
otherwise.  
 
7. AGGRESSIVE COMMERCIAL PRACTICES 
Aggressive commercial practices are commercial practices using harassment, coercion, including 
the use of physical force, or undue influence, that impairs significantly or is likely to impair 
significantly the average consumer's freedom of choice or conduct and thereby causes him or her 
or is likely to cause him or her to take a transactional decision that he would not have taken 
otherwise. 
 
8. THE BLACK LIST OF PROHIBITED PRACTICES 
Annex I of Directive 2005/29 provides a list of the commercial practices that must be 
considered, in all circumstances, as unfair and therefore prohibited, such as: 
• pretending to be a signatory to a code of conduct or to have a trust mark or quality mark 
when it is not true,  
• using bait advertising (when the low-priced product is not available)  
• stating that a product can legally be sold when it cannot. 
• using ‘advertorial’ (avertising made in a form of an editioral copy)  
• making persistent and unwanted solicitations by telephone, fax, e-mail or other remote 
media except in circumstances and to the extent justified under national law to enforce a 
contractual obligation. 
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B. General prohibition of unfair commercial practices 
 
The Directive bans unfair commercial practices in the European Union. This principle applies 
when a practice is contrary to the requirements of professional diligence and when it distorts or 
could distort the behaviour of the average consumer.  
 
Some additional criteria are provided in order to assess if a commercial practice is unfair. The 
Directive defines the misleading practices and the aggressive practices, but also provides a black 
list of the commercial practices that must be prohibited in all the Member States.  
 
Consumer groups considered as vulnerable receive a higher level of protection in order to 
prevent the exploitation of consumers whose characteristics make them particularly vulnerable to 
unfair commercial practices. Indeed, where a commercial practice specifically targets a particular 
group, such as children, the impact of the commercial practice must be assessed from the 
perspective of the average member of that group. 
 
 
XI. DIRECTIVE 1997/7 ON THE PROTECTION OF 
CONSUMERS IN RESPECT OF DISTANCE CONTRACTS 
 
A. Key concepts 
 
1. DISTANCE CONTRACT 
A distance contract is any contract concerning goods or services concluded between a supplier 
and a consumer under an organised distance sales or service-provision scheme run by the 
supplier, who, for the purpose of the contract, makes exclusive use of one or more means of 
distance communication up to and including the moment at which the contract is concluded. 
 
2. CONSUMER 
A consumer is any natural person who, in contracts covered by this Directive, is acting for 
purposes which are outside his trade, business or profession.  
 
3. SUPPLIER 
A supplier is any natural or legal person who is acting in his commercial or professional capacity. 
 
4. MEANS OF DISTANCE COMMUNICATION 
Means of distance communication are any means that, without the simultaneous physical 
presence of the supplier and the consumer, may be used for the conclusion of a contract between 
those parties.  
 
B. Information duty 
 
Prior to the conclusion of any distance contract, the supplier must provide the consumer with the 
following information: 
• the identity of the supplier and, in the case of contracts requiring payment in advance, his 
address; 
• the main characteristics of the goods or services; 
• the price of the goods or services including all taxes; 
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• delivery costs, where appropriate; 
• the arrangements for payment, delivery or performance; 
• the existence of a right of withdrawal; 
• the cost of using the means of distance communication, where it is calculated other than 
at the basic rate; 
• the period for which the offer or the price remains valid; 
• where appropriate, the minimum duration of the contract in the case of contracts for the 
supply of products or services to be performed permanently or recurrently. 
 
Those information shall also be confirmed by writing or in another durable medium available  
(i.e. electronic format or an email) to the consumer, in good time during the performance of the 
contract (for instance, just after the conclusion of the contract), and at the latest at the time of 
delivery, unless the information has already been given to the consumer prior to conclusion of 
the contract in writing or on another durable medium available and accessible to him or her. 
 
The written confirmation must include also: 
• the conditions and procedures for exercising the right of withdrawal; 
• the place to which the consumer may address any complaints; 
• the information on after-sales services and guarantees; 
• the conditions under which the contract may be rescinded. 
 
C. Right of withdrawal 
 
When a consumer enters a contract at distance, he must benefit from a right of withdrawal 
allowing him or her to cancel the contract during 7 days without any penalty. 
 
When the supplier does not inform the consumer on this right of withdrawal, the period is 
extended to 3 months.  
 
If the consumer exercises his right of withdrawal, the supplier has to repay the amounts already 
paid within 30 days. The only charge that may be made to the consumer because of the exercise 
of his right of withdrawal is the direct cost of returning the goods. 
 
The right of withdrawal does not apply to some types of contract, such as: 
• for the provision of services if performance has begun, with the consumer's agreement, 
before the end of the seven working day period; 
• for the supply of goods or services the price of which is dependent on fluctuations in the 
financial market and which cannot be controlled by the supplier; 
• for the supply of goods made to the consumer's specifications or clearly personalized or 
which, by reason of their nature, cannot be returned or are liable to deteriorate or expire 
rapidly; 
• for the supply of audio or video recordings or computer software which were unsealed by 
the consumer; 
• for the supply of newspapers, periodicals and magazines. 
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We have so far provided a general overview of the principles of liability and consumer protection 
in the EU and their application to eHealth (Part I) and a detailed analysis of the key legislation 
(Part II). Part III will look at those principles and definitions in practice by using a series of 
fictional cases. 
 
Each case vignette has been constructed on the basis of fictional case histories to outline the way 
in which legislation might be applied in practice. The case vignettes are not ‘real’ cases as such 
but are informed by reports of real cases and are grounded in the reality of medical practice.  
 
In order to make best use of the case vignettes the reader should refer back to Part II to ensure 
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CASE VIGNETTE 1 
 
Bert Bemelmans, a 38-year old Belgian, was born with the rare disease, Nafram syndrome, which 
he inherited from his father. As the son of a Nafram Syndrome patient, Bert was diagnosed early 
on.  Barring the limitation on strenuous athletic activity incurred by Nafram Syndrome, Bert 
enjoys a regular life. 
 
Bert’s mother’s career as an economist took the family from Belgium to the UK in 1986. But Bert 
Jr. returned for his masters’ degree and settled down in Liège, while his parents remained in 
Bristol. Bert Bemelmans Senior passed away in 2004 in the UK. Bert Jr and his wife Barbara have 
two children, Ben 18 and Beverly 16. 
  
Ben is a computer addict, spending most of his waking moments online. His health is generally 
good, as Ben is fortunate not to have inherited Nafram Syndrome.  But, Ben does have one 
problem that occurs in certain rare forms of Nafram Syndrome, sleep apnoea, which is 
characterized by loud snoring and more seriously by respiratory difficulty while sleeping.  Last 
summer, Ben’s stay at summer camp was marred by his tent-mates making fun of the noise. Ben 
was determined to put an end to the problem without telling his family.  
 
Late one night, Ben Googled “snoring” “treatment” and found an advertisement for an 
international online pharmacy, offering a one week over the counter (OTC) cure for snoring. The 
effect of the treatment was guaranteed to last a minimum of six months. Ben used his credit card 
to order the item. 
 
The product named HypnoNix arrived at the Bemelmans home in Liège in only three days, 
despite the fact that the international pharmacy warehouse was situated on Cyprus. Ben was a 
little bit surprised to note that the product leaflet was in Greek, but the information on the 
website in English was more than sufficient. In any event, Ben was very happy with his purchase, 
because he recorded his sleep between two and three in the morning and noted that he no longer 
snored. 
 
However, one month into the treatment, Ben developed sudden and severe shortness of breath 
and nosebleeds. Wondering whether HypnoNix could be responsible for this, he returned to the 
website and read the fine print. HypnoNix can induce a variety of respiratory ailments. Ben had 
not noticed that information the first time around and wondered if it had indeed appeared on the 
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Young Ben thought he just found the perfect solution to his snoring problem after reading an 
advertisement for HypnoNix on the website of an international pharmaceutical company which 
warehouse is established on Cyprus. In theory he should have been cured for at least six months 
after a one-week cure. HypnoNix was delivered over the counter (OTC) and the product leaflet 
was written in Greek, a language he does not understand. The snoring stopped but one month 
later Ben developed breathing problems and nosebleeds. He returned to the website and read the 
fine print and discovered that HypnoNix could have side effects such as respiratory problems. 
He is not sure that this information was on the website when he ordered the HypnoNix cure. 
 
What went wrong in this case? To answer this question we have to consider the different 
regulations applicable to Ben’s situation.  
 
1. DIRECTIVE ON ECOMMERCE 
The first question is to know if we are in presence of an information society service falling under 
the scope the eCommerce Directive (online promotion and sale of HypnoNix).  
 
We may assume that the online offering (without the need of an over-the-counter medication 
which required no prescription by a medical professional) of a one week cure for snoring is an 
information society service, since it does not seem to require the physical examination of the 
patient. This is however dependant on the drug not requiring a prescription to be sold, since in 
many EU countries an on-line prescription may only be made where the doctor and patient have 
an existing relationship in which the doctor has previously met with the patient face-to-face. In 
some countries medical advice by electronic communication (e-mail or website) is never 
permitted, even if such a relationship already exists. 
 
If however HypnoNix is not a prescription drug and is not offered on the basis of a medical 
consultation, we have a simple eCommerce relationship in which the pharmaceutical company 
would be the service provider of this information society service and Ben would be the recipient 
of the service.  
 
The information society service also includes a commercial communication as it is promoting the 
sale of HypnoNix - a medicinal product.  
 
We assume that the service provider is established in Cyprus . Hence the Cypriot Law will apply 
to this eCommerce activity according to the principle of country of origin.  This means that first 
we need to establish is the service provider has complied with his duties as an information society 
service provdier. These duties refer mainly to the information which must be given to the 
consumer and to the procedure of purchasing medicinal products by electronic means.  
 
a. Information duties 
The advertisement for Hypnonix should comply with the general information due for any 
information society service (i.) and with the conditions applicable to any commercial 
communication (ii.).  
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i. General information duty 
The following information should have appeared on the website: 
 
• the name of the service provider (the pharmaceutical company making Hypnonix , or the 
vendor  ) ;  
• the geographic address at which the service provider is established – in Cyprus ; 
• the details of the service provider, including his electronic mail address, which allows him 
to be contacted rapidly and communicated with in a direct and effective manner ;  
• where the service provider is registered in a trade or similar public register, the trade 
register in which the service provider is entered and his registration number, or equivalent 
means of identification in that register ;  
• where the activity is subject to an authorisation scheme, like the sale of pharmaceutical 
products, the particulars of the relevant supervisory authority. 
• The Value Added Tax number should also appeared on the advertisement.  
• The price of the Hypnonix cure should appear on the website and should indicate if it is 
inclusive of tax and  delivery costs as the product will be sent from Cyprus to Belgium.  
 
ii. Conditions applicable to the commercial communication 
The online advertisement is a commercial communication regarding the eCommerce Directive. 
Hence the advertisement should comply with further conditions such as i.e.:  
 
• the commercial communication has to be clearly identifiable as such; 
• the natural or legal person on whose behalf the commercial communication is made has 
to be clearly identifiable;  
• promotional offers, such as discounts, premiums and gifts, if permitted in Greek Law, has 
to be clearly identifiable as such, and the conditions which are to be met to qualify for 
them has to be easily accessible and be presented clearly and unambiguously.  
 
b. Purchase of HypnoNix by electronic means 
Ben is allowed to purchase HypnoNix by electronic means according to the eCommerce 
Directive. But this does not prevent the application of other rules (Greek or Belgian) opposing 
the sale of medicine through the Internet i.e. for public health safety reasons or requiring a 
medical prescription.  
 
If the conclusion of the contract by electronic means is allowed by the local laws, it will have to 
comply with special conditions: prior to placing the order, Ben should have received some 
information regarding the contractual procedure (the applicable codes of conduct and the 
contract terms and the general conditions). 
 
i.  Prior information on the contractual procedure 
If the online OTC sale of HypnoNix is lawful in Greece and in Belgium, the pharmaceutical 
company still has to provide Ben with some information regarding the contractual procedure 
leading to the purchase of the medicine, prior the placing of the order. This information must be 
clear, understandable and unambiguous:  
• the different technical steps to follow to conclude the contract;  
• whether or not the concluded contract will be filed by the pharmaceutical company and 
whether the contract will be accessible;  
• the technical means for identifying and correcting input errors prior to the placing of the 
order;  
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• the languages offered for the conclusion of the contract. 
 
ii. Prior information on codes of conduct 
The pharmaceutical company must indicate any relevant codes of conduct to which it subscribes 
and information on how those codes can be consulted electronically. 
 
iii. Contractual terms and General conditions 
The contractual terms and general conditions must be made available in a way allowing Ben to 
store and reproduce them.  
 
iv. Placing of the order 
Prior to the placing of the order the pharmaceutical company has to make available to Ben 
appropriate, effective and accessible technical means allowing him to identify and correct input 
errors (for instance the number of ordered doses or cures, the delivery address, the credit card to 
be charged).  
 
Then the pharmaceutical company must acknowledge the receipt of Ben's order without undue 
delay and by electronic means.  
 
2. DIRECTIVE ON BUSINESS-TO-CONSUMER COMMERCIAL PRACTICES 
Considering the Directive on Business to Consumer Commercial Practices, the question to 
address is to know if the online promotion and sale of HypnoNix might constitute unfair 
commercial practices. The question is delicate. We could consider several hypotheses.  
 
First the advertisement could constitute an unfair commercial practice if the website states that 
HypnoNix may be sold online OTC when it is not true regarding Greek or Belgian Law.  
 
The commercial communication might also be an unfair commercial practice if the website refers 
to a code a conduct or a trustmark with whom the site does not comply.   
 
The unfair practice could also result from the use of advertising under the form of a medical 
editorial. In the same logic the company has to avoid misleading the consumer when providing 
false or incomplete information. Therefore the phrasing of the advertisement should be carefully 
reviewed.  
 
In summary the company has to be very cautious when promoting HypnoNix through its 
website. Otherwise the company could face lawsuits according to the national measures taken 
when transposing the directive in Belgian Law (i.e., complaint by the Belgian Ministry of 
Economics Affairs or of Public Health).  
 
3. DIRECTIVE ON DISTANCE CONTRACTS 
Ben has purchased HypnoNix by a distance contract. Hence, prior to the conclusion of this 
distance contract, the pharmaceutical company should have provided him with at least the 
following information:  
• the identity of the supplier and, if payment in advance is required, his address; 
• the main characteristics of HypnoNix; 
• the price of HypnoNix including all taxes; 
• delivery costs; 
• the arrangements for payment and delivery; 
• the existence of a right of withdrawal; 
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• the period for which the offer or the price remains valid.  
 
Ben should have received a written confirmation or in another durable medium available (i.e. 
electronic format or an email) of the order, unless the information has already been given prior to 
conclusion of the contract. 
 
The written confirmation must include also: 
• the conditions and procedures for exercising the right of withdrawal; 
• the place to which the consumer may address any complaints; 
• the information on after-sales services and guarantees; 
• the conditions under which the contract may be rescinded. 
 
If Ben had chosen to exercise his right of withdrawal the pharmaceutical company should have 
repaid him the price within thirty days. But Ben could be charged with the cost of the returning.  
 
4. DIRECTIVE ON CONSUMER GOODS 
Under this Directive Ben is entitled to receive a medicine conform to the description given by the 
pharmaceutical company. HypnoNix must show the quality and the regular performances of such 
medicine and which Ben could reasonably expect given the nature of the product and taking into 
account any public statements on the specific characteristics of HypnoNix made by the 
pharmaceutical company particularly in advertising or on labelling.  
 
The seller of HypnoNix will be liable for any lack of conformity existing at the time of the 
delivery. The final seller is entitled to suit previous seller of the product.  
 
The pharmaceutical company could try to escape from her liability notably by claiming that Ben 
could not be unaware of the lack of conformity. 
 
But the remedy for the lack of conformity will not necessarily satisfy Ben. Indeed if he succeeds 
in his action, the Directive only entitles him to ask for a conform product or an appropriate 
reduction to the price or the cancellation of the contract.  
 
5. DIRECTIVE ON GENERAL PRODUCT SAFETY  
The Directive on General Safety Product could be interesting for Ben. Indeed HypnoNix should 
not present any risk for Ben or only the minimum risks compatible with its use. Here HypnoNix 
presented severe side effects. Hence it could be argued that HypnoNix is a dangerous product.  
 
In any case the company should have provided Ben with enough information to enable him to 
assess the risks linked with the use of HypnoNix. In this case we could argued the company 
should have withdrew HypnoNix from the market and informed consumers and recalled the 
products already supplied to consumers. There should have been a monitoring of the product 
safety and a collaboration with the competent authorities to avoid the risks.  
 
National authorities also have a role to play in the monitoring of the product safety and they have 
to take appropriate actions regarding dangerous products such as HypnoNix.  
 
6. DIRECTIVE CONCERNING DEFECTIVE PRODUCTS 
If HypnoNix is industrially produced it falls under the scope of the Defective Product Directive.  
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HypnoNix could be regarded as a defective product if it does not provide the safety which a 
person is entitled to expect taking all circumstances into account. In this case it is likely that 
HypnoNix is defective.  
 
If HypnoNix is defective, Ben may assign the producer for damages caused by personal injuries. 
He must introduce his suit in a three year period starting from the day on which he became aware 
or should reasonably have become aware of the damage, the defect and the identity of the 
producer. In any case the producer’s liability is limited to a ten year period from the date on 
which the producer put the product into circulation.  
 
7. DIRECTIVE ON MEDICINAL PRODUCTS FOR HUMAN USE 
HypnoNix is a medicinal product. Hence it cannot be put into the market without a prior 
marketing authorization granted by the national competent authorities.  
 
Once granted with a marketing authorization the advertisement for HypnoNix have to comply 
with numerous rules. If HypnoNix did not receive a marketing authorization, no advertising 
might be done except if it is considered as a homeopathic medicine. If HypnoNix is not a 
homeopathic medicine and was granted with a marketing authorization, its advertising should 
comply with several conditions (encouraging rational use, objective presentation of its properties, 
etc.) including special warning on side effects.  
 
No advertising is allowed for HypnoNix if its delivery requires a medical prescription or the 
intervention of a medical practitioner of a pharmacist.  
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CASE VIGNETTE 2 
 
Sophie and Sandrine Sandeau are identical twins with a congenital cardiac disorder that led to the 
implantation of their first pacemakers at age 40.  
 
Sophie is a biologist with the French Medical Research Institute in Paris, and Sandrine is a 
mystery novelist, well known in the Bordeaux area for her vineyard murder series. Both sisters 
support the work of the French Association of Congenital Cardiac Disorders.  
 
Six years after the first pacemakers, Professor Serge Simon, the head cardiac surgeon at a state of 
the art French hospital performed an innovative surgical technique on the sisters at six month 
intervals, first Sophie and then Sandrine.  
 
Professor Simon and his cardiologist colleague Dr. Samuel Stephane next recommended that 
Sophie and Sandrine be equipped with the latest devices, one implantable, the other wearable. 
 
Sophie was monitored remotely thanks to PhysioImplant®, an implantable Finnish monitoring 
and dosage device. PhysioImplant® provides early warning of cardiac failure and adjusts 
medication dosages accordingly. Measurements are taken automatically, and data communicated 
continuously to the cardiac monitoring centre in suburban Paris.  
 
Sandrine, on the other hand, was prescribed, e-Vest®, a “wearable” electronic monitoring device, 
implanted in a special lightweight sleeveless vest. The sensors imbedded in the vest, continuously 
monitored Sophie’s, heart rate, heart rhythm and medication requirements and transmitted the 
data to the same cardiac centre. 
 
Dr Stephane was very pleased with the initial results. The Sandeau sisters were much less anxiety-
ridden than they had been prior to use of the monitoring systems. They hoped nonetheless that 
they would not have to remain under monitoring surveillance in twelve months’ time. 
 
Unfortunately, after two months, Sophie suddenly developed cardiac oedema and had to be 
hospitalised. Receiving too little medication because of a defect in the PhysioImplant® system, 
Sophie required immediate hospitalisation. Fortunately, the night nurse at the cardiac monitoring 





This case covers the situation of Sophie and Sandrine Sandeau. We are going to review the main 
rules applicable to their respective situations and highlight the possible remedies for Sophie. 
 
Sophie’s cardiac implant 
 
Sophie benefits from an implantable cardiac medical device with a drug distribution function, 
coupled with a telemonitoring service.  
 
1. THE TELEMONITORING SERVICE 
The telemonitoring service constitutes an information society service. The telemonitoring service 
is covered  by the French Law according to the principle of country of origin since  the service 
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provider is established in France and will thus have to respect the French law developed under 
the eCommerce Directive as well as French contract law. 
 
First we have to highlight the duties that fall upon the service provider regarding the rules 
applicable to this information society service. These duties refer mainly to the information to be 
provided to the recipient of the service.  
 
The service provider has to give to Sophie at least the following information concerning the 
telemonitoring service:  
 
• the name of the service provider ;  
• the geographic address at which the service provider is established : the company seems 
to be located on France ; 
• the details of the service provider, including his electronic mail address, which allow him 
to be contacted rapidly and communicated with in a direct and effective manner ;  
• where the service provider is registered in a trade or similar public register, the trade 
register in which the service provider is entered and his registration number, or equivalent 
means of identification in that register ;  
• where the activity is subject to an authorisation scheme, like the provision of healthcare 
service, the particulars of the relevant supervisory authority. 
• The Value Added Tax number should also be indicated, 
• The price of the telemonitoring service should appear and indicate if it is inclusive of tax.  
 
 
2. THE IMPLANTABLE MEDICAL DEVICE WITH THE DRUG DISTRIBUTION FUNCTION 
Sophie suffered a malfunctioning of her implantable medical device combined with a drug 
distribution function. Happily the nurse at the monitoring centre reacted quickly and on an 
appropriate way. 
 
But what kind of liabilities could arise in this case regarding the European Legal Framework if the 
nurses had not acted so quickly? 
 
a. Directive on the sale of consumer goods 
Under this Directive, Sophie is entitled to receive a device conformant to the description given 
by the seller. The implant must show the quality and the regular performances of such a device 
and which Sophie could reasonably expect given the nature of the product and taking into 
account any public statements on the specific characteristics of the Implant made by the seller 
particularly in advertising and on labelling.  
 
The seller of the Implant will be liable for any lack of conformity existing at the time of the 
delivery. The final seller is entitled to suit previous seller of the product.  
 
But the remedy for the lack of conformity will not necessarily satisfy Sophie. Indeed if she 
succeeds in an action, the Directive only entitles her only to ask for a conformant product or an 
appropriate reduction to the price of the one she has or the cancellation of the contract.  
 
b. Directive on General Product Safety  
The Directive on General Safety Product could be useful to Sophie. The Implant should not have 
presented any risk for Sophie or only the minimum risks compatible with its use. Here the 
Implant had a defect. Hence it could be argued that the PhysioImplant® is a dangerous product.  
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The company should have provided Sophie with enough information to enable her to assess the 
risks linked with the use of the Implant. In this case we could argue that the company should 
have withdrawn the PhysioImplant® from the market, informed consumers and recalled the 
products already supplied to consumers. There should have been a monitoring of the product 
safety and a collaboration with the competent authorities to avoid such risks.  
 
National authorities also have a role to play in the monitoring of the product safety and they have 
to take appropriate actions regarding dangerous products such as the Implant.  
 
c. Directive concerning Defective Products 
If the Implant is industrially produced it falls under the scope of the Defective Product Directive.  
 
The PhysioImplant® could be regarded as a defective product if it does not provide the safety 
which a person is entitled to expect taking all circumstances into account. In this case it is likely 
that the Implant is defective.  
 
If the Implant is defective, Sophie may sue the producer for damages caused by personal injuries 
she suffered as a result of using the defective product She must introduce her suit in a three year 
period starting from the day on which she became aware or should reasonably have become 
aware of the damage, the defect and the identity of the producer. In any case the producer’s 
liability is limited to a ten year period from the date on which the producer put the product into 
circulation.  
 
d. Directive relating to active implantable medical devices 
Sophie bears an active implantable medical device administering a medicinal product. The 
medicinal product has to have been granted a marketing authorization as set out in the Directive 
on Implantable Medical Devices. 
 
The medical device must comply at least with the essential requirements set out in the Annex 1 of 
the Directive relating to active implantable medical devices.  
 
In this case as the device had compromised the health of Sophie, the French government must 
take all appropriate measures to withdraw the device from the market. The French Government 
must also inform immediately the European Commission of the measure and indicates its 
reasons. The information regarding such incident has to be recorded and evaluated in a 
centralized manner.  
 
 
Sandrine’s wearable medical device in her sleeveless vest 
 
Sandrine benefits from a wearable cardiac medical device with a medication requirement 
function, coupled with the same telemonitoring service as her sister Sophie.  
 
1. THE TELEMONITORING SERVICE 
The telemonitoring service constitutes an information society service regarding the eCommerce 
Directive.  The service provider is the cardiac monitoring centre in Paris. Sandrine is the recipient 
of the telemonitoring service. The telemonitoring service is covered by the French Law according 
to the principle of country of origin if the service provider is well established in France.  
 
EHEALTH GOODS & SERVICES:  
ISSUES OF LIABILITY AND CONSUMER PROTECTION 
 
30-CE-0041734/00-55   « Legally eHealth » D.3 (PUB) v10.0, p.57/66 
 
The cardiac monitoring centre in Paris  has a duty as  service provider which concenrn primarily 
information it must make available to the recipient of the service. 
 
The service provider has to provide Sandrine with at least the following information concerning 
the telemonitoring service:  
 
• the name of the service provider ;  
• the geographic address at which the service provider is established : the company seems 
to be located on France ; 
• the details of the service provider, including his electronic mail address, which allow him 
to be contacted rapidly and communicated with in a direct and effective manner ;  
• where the service provider is registered in a trade or similar public register, the trade 
register in which the service provider is entered and his registration number, or equivalent 
means of identification in that register ;  
• where the activity is subject to an authorisation scheme, like the provision of healthcare 
service, the particulars of the relevant supervisory authority, 
• the Value Added Tax number should also be indicated, 
• the price of the telemonitoring service should appear and indicate if it is inclusive of tax.  
 
2. THE WEARABLE MEDICAL DEVICE WITH THE MEDICATION REQUIREMENT FUNCTION 
Sandrine’s eVest is a medical device that must comply with several rules.  
 
a. Directive on the sale of consumer goods 
Under this Directive Sandrine is entitled to expect a medical device (the eVest) which conforms 
to the description given by the seller. The eVest must show the quality and the regular 
performances of such product and which Sandrine could reasonably expect given the nature of 
the product and taking into account any public statements on the specific characteristics of the 
eVest made by the seller particularly in advertising and on labelling.  
 
The seller of the eVest will be liable for any lack of conformity existing at the time of the 
delivery. The final seller is entitled to sue the previous seller of the product.  
 
b. Directive on General Product Safety  
The eVest should not present any risk for Sandrine or only the minimum risks compatible with 
its use. Here the eVest does not seem to be dangerous.  The company should provide Sandrine 
with enough information to enable her to assess the risks linked with the use of the eVest. In case 
of an incident the company should consider the withdrawal of the Vest from the market and the 
information of the consumers and the recall of the products already supplied to consumers. 
There should be a monitoring of the product safety and a collaboration with the competent 
authorities to avoid the risks.  
 
National authorities also have a role to play in the monitoring of the product safety and they have 
to take appropriate actions regarding dangerous products.  
 
c. Directive concerning Defective Products 
If the eVest is industrially produced it falls under the scope of the Defective Product Directive.  
 
The eVest could be regarded as a defective product if it does not provide the safety that a person 
is entitled to expect taking all circumstances into account. In this case the eVest does not seem to 
be defective.  
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If the eVest appears to be defective, Sandrine could sue the producer for damages caused by 
personal injuries arising from reasonable use of the eVest. She would have to introduce her suit 
in a three year period starting from the day on which she became aware or should reasonably 
have become aware of the damage, the defect and the identity of the producer. In any case the 
producer’s liability is limited to a ten year period from the date on which the producer put the 
product into circulation.  
 
d. Directive relating to active implantable medical devices 
The eVest does not qualify as an implantable medical device, since it is a near body device rather 
than one physically implanted into the body. 
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CASE VIGNETTE 3 
 
Dr Caroline Carrington is a general practitioner who recently arrived in a busy group practice, in 
Loch Harlow, Lannockshire, Scotland.  Caroline replaced Dr. Charles Cramer, when he retired in 
May 2006, inheriting his carefully handwritten records. Dr Carrington, a pragmatic professional, 
wanted to switch to digital records as quickly as possible, before multiplying her own additions to 
the files.  
 
Dr Carrington also wanted to acquire a properly authorized electronic signature and begin to 
generate e-prescriptions. The scanned signature that she used for transmitting certain 
correspondence did not satisfy Dr Carrington.  She wanted the pharmacists (chemists) to be 
certain that she and she alone had authorized the prescription. Since Dr Carrington wasn’t sure 
that either of the SoftMicro® devices, the pen tablet or the digital pen were truly stabilized, Dr 
Carrington decided to go with a simple encryption signature software that she purchased online 
from a Loch Harlow internet service provider. 
 
Dr Carrington was looking forward to her first day of ePrescribing with the electronic signature. 
Unfortunately that day she had to attend to the German national ping-pong team whose bus tour 
took them through Lannockshire on their way to France. Half of the team needed an antibiotic 
that would have to be ordered for delivery the next day in Lille, and Dr Carrington did not know 
how to ePrescribe beyond the borders of Scotland… 
 
Fortunately, Dr Carrington’s last patient of the day, Lana Lipton, was a Lannockshire resident 
and Dr Carrington was able to “write” her first ePrescription for Lana’s anti-ulcer treatment and 
sign it electronically. Lana was pleased that she did not have to wait at the pharmacy (chemist’s), 
because her order was ready when she got there.  
 
Dr Carrington’s next project was to set up her own blog to promote the use of eHealth tools to 




Dr Carrington wishes to use an authorized electronic signature for ePrescription in her Member 
State and within Europe. 
 
To benefit from the same recognition as a hand-written signature, the electronic signature must 
be an advanced signature complying with the following requirements: 
 
• It must be based on a qualified certificate; 
• The certificate must have been issued by a service-provider who possesses the 
requirements foreseen in Annex II to the Directive on Electronic Signature; 
• It must be created by a secure-signature-creation device which meets the requirements 
laid down in Annex III of the Directive on Electronic Signature; 
 
As we already know an electronic signature means data in electronic form which are attached to 
or logically associated with other electronic data and which serve as a method of authentication. 
And an advanced electronic signature is an electronic signature that meets the following 
requirements: 
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(a) it is uniquely linked to the signatory; 
(b) it is capable of identifying the signatory; 
(c) it is created using means that the signatory can maintain under his sole control; and 
(d) it is linked to the data to which it relates in such a manner that any subsequent change 
of the data is detectable. 
 
A certificate is an electronic attestation which links signature-verification data to a person and 
confirms the identity of that person and a qualified certificate is a certificate which meets the 
requirements laid down in Annex I of the Directive on electronic signature and is provided by a 
certification-service-provider who fulfils the requirements laid down in Annex II of the same 
Directive.  
 
In this case it is not sure that the solution used by Dr Carrington is satisfactory enough for 
producing ePrescriptions. She really needs an advanced electronic signature and a qualified 
certificate. She also has to comply with national rules applicable to medical prescription and their 
administrative aspects.  
 
To know if she could have prescribed antibiotics to the German ping-pong team to be delivered 
in France she should have consulted the French Law regarding the recognition of her medical 
education (professional equivalence) and regarding the issue of the intervention of the French 
social security system to allow the reimbursement of the antibiotics. 
 
If she wants to promote eHealth through the creation of a blog, she has to consider if it 
constitutes an information society service. If the answer is positive (and it is likely going to be 
positive) she has to comply with the conditions applicable to such service.  
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CASE VIGNETTE 4 
 
Wilhelm Wolfgang, 50, a building construction manager in Stuttgart, has suffered from multiple 
allergies both respiratory and dermatological, since he began working on construction projects at 
age 18. Wilhelm, a non-smoker, has generally been in good health, other than the recurrent 
allergies. Unfortunately his most recent routine x-ray has revealed some suspicious areas on the 
upper right lung. 
 
Wilhelm’s sister Wanda also suffered from allergies, and in particular pollen-related ones. She 
decided to look around on the Internet for solutions to her problems. Three web sites caught her 
attention.  
 
The first was called “Allergies and Yoghurt”. On this page, she learned of the existence of a 
special Bulgarian yoghurt reputed for its anti-allergic properties. Wanda noted that the web site 
displayed a quality trustmark from the Bulgarian Dairy Association and found the articles 
interesting. But, she decided to eliminate that web site from her sources, when she realized that 
there was no contact information or even company name for the sponsor of the web site. She 
wondered if the Bulgarian Dairy Association would not have a conflict of interest regarding the 
yoghurt’s health qualities. 
 
The second web site was the “Austrian national allergy web site”, on which she noticed a product 
that was not available in Germany. The web site offered product information regarding an over-
the-counter (OTC) allergy treatment from an Austrian company that had been started by German 
owners, hoping to avoid German regulations. Wanda wondered whether it was legal for her to 
order such a product from Austria. 
 
Wanda also noted that the web site offered a 24 hour help number. She phoned the service and 
found the line busy, so that it took her several hours to get through. When she did get through, 
the nurse was cheery. However, the nurse’s main task of determining whether Wanda required an 
immediate medical appointment could not be achieved, since the web site was reserved to 
Austrian nationals.  Ever the optimist, Wanda decided she would at least tell her Austrian cousin 
Wilhelmina about the web site, since Wilhelmina also suffered from allergies. 
 
The third web site was titled “Testing for Allergies”. It presented information about the various 
tests that an allergy-sufferer could find in pharmacies or by contacting a physician. She noted that 
this web site was produced by a pharmaceutical manufacturer who provided full contact 
information; secondly, the German Allergy Association displayed its logo on the site. Wanda 
printed out the page and planned to bring it to her pharmacist the next day. Her pharmacist was 




Wolfgang’s sister looked at three websites in order to find a solution to her allergic problems.  
 
The three Health related websites consulted by Wanda should at least comply with the Quality 
Criteria applicable to the Health Related Websites (COM (2002)667final, 29 nov.2002). In short 
these criteria are the following:  
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Transparency and honesty 
• Transparency of the provider including the name, mail address and email of the person or 
organisation in charge of the website; 
• Transparency of the purpose and objective of the website; 
• Clear definition of the targeted audience; 
• Sources of funding of the website. 
 
Authority 
• Clear statement of source for all information provided and date of publication of sources 
• Name and credentials of all information providers including dates at which credentials 
were received 
 
Privacy and data protection 
• Data protection must be ensured including protection against invisible data processing 
 
Updating of information 
• Clear and regular updating of the website with date of up-date clearly displayed for each 
page and / or item as relevant + regular checking of relevance of information 
 
Accountability 
• Accountability - User feedback and appropriate oversight responsibility 
• Responsible partnering - All efforts should be made to ensure that partnering or linking 
to other websites is undertaken only with trustworthy individuals and organisations who 
themselves comply with relevant codes of good practices 




• Attention to guidelines on physical accessibility as well as general findability, searchability, 
readability, usability, etc. 
 
Although the guidelines are not legally binding, many of the principle in the guidelines are 
reflected also in the legislation that is examined in more detail below. 
 
1. ALLERGIES AND YOGHURT WEBSITE 
If we consider the website Allergies and Yoghurt as an information society service (this 
qualification is due at first view mainly to the promotion of Bulgarian Yoghurt on the website), it 
has to comply with several rules from the eCommerce Directive.  
 
The law applicable to this information society service will be the law of the country where the 
service provider is established. In the present case we ignore the service provider location. If the 
service provider is established outside Europe there could be another problem in the 
determination of the applicable law.  
 
Normally in Europe the service provider should give at least the following information:  
• his name;  
• the geographic address at which he is established;  
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• his details, including his electronic mail address, which allow him/her to be contacted 
rapidly and communicated with in a direct and effective manner;  
• where he is registered in a trade or similar public register, the trade register in which he is 
entered and his registration number, or equivalent means of identification in that register;  
• where the activity is subject to an authorisation scheme, the particulars of the relevant 
supervisory authority. 
 
In this case there is no information concerning the service provider.  
 
On the other hand it must be questioned if the website does not promote directly or indirectly 
the goods of a company. If the answer is positive the information society service constitutes a 
commercial communication and hence it has to comply with some additional rules: 
• the commercial communication has to be clearly identifiable as such;  
• the natural or legal person on whose behalf the commercial communication is made has 
to be clearly identifiable;  
• promotional offers, such as discounts, premiums and gifts, where permitted in the 
Member State where the service provider is established, has to be clearly identifiable as 
such, and the conditions which are to be met to qualify for them has to be easily 
accessible and be presented clearly and unambiguously. 
 
In the present case there is no information on the person on whose behalf the commercial 
communication is made.  
 
Then we could discuss the quality trustmark from the Bulgarian Dairy Association displayed on 
the website as an unfair commercial practice.  
 
Finally we could consider the dangerousness of the promotion of the yoghurt as an efficient 
medicine against allergies. More especially we could wonder if the yoghurt should not, as a 
consequence of its presentation as a possible cure for allergies, be subject to a marketing 
authorization as a medicinal product. We have to remember that no advertising may be made for 
a medicinal product for which no marketing authorization has been granted except if the yoghurt 
may be seen as a homeopathic medicine. If the yoghurt is a homeopathic medicine or is an 
authorized medicinal product, the advertising has still to comply with special rules regarding the 
advertisement of medicinal product (encourage the rational use of the medicinal product, 
objective presentation of its properties, etc.). Some medicinal products may not be subject to 
advertising notably such as those requiring the intervention of a medical practitioner or of a 
pharmacist.  
 
2. AUSTRIAN NATIONAL ALLERGY WEBSITE 
The Austrian National Allergy Website offers information on an Over The Counter allergy 
treatment from an Austrian Company started by Germans willing to avoid German Regulations.  
 
The website is thus an information society service including commercial communication as it 
promotes a special product.  
 
The law applicable to this information society service is the law of the country where the service 
provider is established – here the Austrian Law. There might be exceptions to this principle in 
Germany i.e. for the protection of public health.  
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Normally the service provider should give at least the following information:  
• his name;  
• the geographic address at which he is established;  
• his details, including his electronic mail address, which allow him/her to be contacted 
rapidly and communicated with in a direct and effective manner;  
• where he is registered in a trade or similar public register, the trade register in which he is 
entered and his registration number, or equivalent means of identification in that register;  
• where the activity is subject to an authorisation scheme, the particulars of the relevant 
supervisory authority. 
 
Some additional requirements have to be met regarding the commercial communication:  
• the commercial communication has to be clearly identifiable as such;  
• the natural or legal person on whose behalf the commercial communication is made has 
to be clearly identifiable;  
• promotional offers, such as discounts, premiums and gifts, if permitted in Austria, has to 
be clearly identifiable as such, and the conditions which are to be met to qualify for them 
has to be easily accessible and be presented clearly and unambiguously. 
 
Finally we could consider the dangerousness of the promotion of the treatment regarding the fact 
it has been banned in Germany. More especially we could question if the treatment should not, as 
a consequence of its presentation as a possible cure for allergies, be subject to a marketing 
authorization as a medicinal product. We have to remember that no advertising may be made for 
a medicinal product for which no marketing authorization has been granted except if the 
treatment may be seen as a homeopathic medicine. If the treatment is a homeopathic medicine or 
is an authorized medicinal product, the advertising has still to comply with special rules regarding 
the advertisement of medicinal product (encourage the rational use of the medicinal product, 
objective presentation of its properties, etc.). Some medicinal products may not be subject to 
advertising notably such as those requiring the intervention of a medical practitioner or of a 
pharmacist.  
 
3. TESTING ALLERGIES WEBSITE 
The last website visited by Wanda is the Testing Allergies Website. As it presents information on 
various allergic tests and is produced by a pharmaceutical company, this is an information society 
service including commercial communications.  
 
The law applicable to this information society service is the law of the country where the service 
provider is established – here the German Law.  
 
Normally the service provider should give at least the following information:  
• his name;  
• the geographic address at which he is established;  
• his details, including his electronic mail address, which allow him/her to be contacted 
rapidly and communicated with in a direct and effective manner;  
• where he is registered in a trade or similar public register, the trade register in which he is 
entered and his registration number, or equivalent means of identification in that register;  
• where the activity is subject to an authorisation scheme, the particulars of the relevant 
supervisory authority. 
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Some additional requirements have to be met regarding the commercial communication:  
• the commercial communication has to be clearly identifiable as such;  
• the natural or legal person on whose behalf the commercial communication is made has 
to be clearly identifiable;  
• promotional offers, such as discounts, premiums and gifts, if permitted in Austria, has to 
be clearly identifiable as such, and the conditions which are to be met to qualify for them 
has to be easily accessible and be presented clearly and unambiguously. 
 
Finally we could question if the treatment should not, as a consequence of its presentation as a 
possible cure for allergies, be subject to a marketing authorization as a medicinal product. We 
have to remind that no advertising may be made for a medicinal product for which no marketing 
authorization has been granted except if the treatment may be seen as a homeopathic medicine. 
If the treatment is a homeopathic medicine or an authorized medicinal product, the advertising 
has still to comply with special rules regarding the advertisement of medicinal product (encourage 
the rational use of the medicinal product, objective presentation of its properties, etc.). Some 
medicinal products may not be subject to advertising notably such as those requiring the 
intervention of a medical practitioner or of a pharmacist.  
 
In this case the website does not seem to sell allergic tests directly to the consumer. Here Wanda 
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PART IV: LEGAL SOURCES 
 
Product safety, liability and consumer protection issues relating to eHealth are on some aspects 
regulated by European regulations that may be presented in three categories: 
 
A. Legal Sources concerning information society 
• Directive 1999/93/EC on a Community framework for electronic signatures 
• Directive 2000/31/EC of the European Parliament and of the Council of 8 June 2000 on 
certain legal aspects of information society services, in particular electronic commerce, in 
the Internal Market ('Directive on electronic commerce') 
 
B. Legal Sources concerning “Business” and Consumer Protection 
• Directive 2005/29/EC of the European Parliament and of the Council of 11 May 2005 
concerning unfair business-to-consumer commercial practices in the internal market 
(Unfair Commercial Practices Directive). This Directive replaces the business-to-
consumer rules in the misleading and comparative advertising Directives (Directive 
84/450/EEC of 10 September 1984 relating to the approximation of the laws, 
regulations and administrative provisions of the Member States concerning misleading 
advertising as modified by Directive 97/55/EC of European Parliament and of the 
Council of 6 October 1997 concerning misleading advertising so as to include 
comparative advertising). Those two Directives still apply to business-to-business 
activities. 
• Directive 97/7/EC on the protection of consumers in respect of distance contracts 
• Directive 1999/44/EC of the European Parliament and of the Council of 25 May 1999 
on certain aspects of the sale of consumer goods and associated guarantees 
• Directive 2001/95/EC of the European Parliament and of the Council of 3 December 
2001 on general product safety 
• European Convention on products liability in regard to personal injury and death of 27 
January 1977 (NB: Council of Europe) 
• Council Directive 85/374/EEC of 25 July 1985 on the approximation of the laws, 
regulations and administrative provisions of the Member States concerning liability for 
defective products as modified by Directive 1999/34/EC of the European Parliament 
and of the Council of 10 May 1999 amending Council Directive 85/374/EEC on the 
approximation of the laws, regulations and administrative provisions of the Member 
States concerning liability for defective products 
• RoHS Directive 2002/95/EC of the European Parliament and of the Council of 27 
January 2003 on the restriction of the use of certain hazardous substances in electrical 
and electronic equipment.  
 
C. Legal Sources concerning Health care 
• Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the 
Member States relating to Active Implantable Medical Devices 
• Directive 98/79/EC on In Vitro Diagnostic Medical Devices 
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November 
2001 on the Community code relating to medicinal products for human use 
• Council Directive 93/42/EEC of 14 June 1993 concerning medical devices 
